



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2453901 C 2011/05/24

(11)(21) **2 453 901**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2002/07/15

(87) Date publication PCT/PCT Publication Date: 2003/01/30

(45) Date de délivrance/Issue Date: 2011/05/24

(85) Entrée phase nationale/National Entry: 2004/01/15

(86) N° demande PCT/PCT Application No.: EP 2002/007842

(87) N° publication PCT/PCT Publication No.: 2003/008370

(30) Priorité/Priority: 2001/07/17 (DE101 35 636.6)

(51) Cl.Int./Int.Cl. *C07C 215/44* (2006.01),
A61K 31/133 (2006.01), *A61P 25/00* (2006.01),
C07D 209/14 (2006.01), *C07D 277/64* (2006.01),
C07D 277/66 (2006.01), *C07D 295/096* (2006.01),
C07D 307/81 (2006.01), *C07D 333/58* (2006.01)

(72) Inventeurs/Inventors:
SUNDERMANN, BERND, DE;
HENNIES, HAGEN-HEINRICH, DE;
ENGLBERGER, WERNER, DE;
WNENDT, STEPHAN, DE

(73) Propriétaire/Owner:
GRUENENTHAL GMBH, DE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : 4-AMINOCYCLOHEXANOLS SUBSTITUES

(54) Title: SUBSTITUTED 4-AMINOCYCLOHEXANOLS

(57) **Abrégé/Abstract:**

The invention relates to substituted 4-aminocyclohexanols, methods for the production thereof, pharmaceuticals containing said compounds, and the use of substituted 4-aminocyclohexanols for producing pharmaceuticals for treating various indications, especially pain.



123

ABSTRACT

The invention relates to substituted 4-aminocyclohexanols, methods for the production thereof, pharmaceuticals containing said compounds, and the use of substituted 4-aminocyclohexanols for producing pharmaceuticals for treating various indications, especially pain.

Substituted 4-aminocyclohexanols

The present invention relates to substituted 4-aminocyclohexanols, to methods of producing them, to pharmaceuticals containing these compounds and to the use of substituted 4-aminocyclohexanols for producing pharmaceutical compositions for the treatment of various indications, in particular of pain.

The heptadecapeptide nociceptin is an endogenous ligand of the ORL1 (Opioid-Receptor-Like) receptor (Meunier et al., Nature 377, 1995, pp. 532-535), which belongs to the family of opioid receptors and may be found in many regions of the brain and the spinal cord (Mollereau et al., FEBS Letters, 341, 1994, pp. 33-38, Darland et al., Trends in Neurosciences, 21, 1998, pp. 215-221). The peptide is characterised by a high affinity, with a K_d value of approximately 56 pM (Ardati et al., Mol. Pharmacol. 51, pp. 816-824), and by high selectivity for the ORL1 receptor. The ORL1 receptor is homologous to the μ , κ and δ opioid receptors and the aminoacid sequence of the nociceptin peptide has a marked similarity to those of the known opioid peptides. The activation of the receptor induced by the nociceptin leads, via the coupling with $G_{i/o}$ proteins to inhibition of the adenylate cyclase (Meunier et al., Nature 377, 1995, pp. 532-535). On the cellular plane also, there are functional similarities between the μ , κ and δ opioid receptors and the ORL1 receptor with respect to activation of the potassium channel (Matthes et al., Mol. Pharmacol. 50, 1996, pp. 447-450; Vaughan et al., Br. J. Pharmacol. 117, 1996, pp. 1609-1611) and inhibition of the L-, N- and P/Q- type calcium channels (Conner et al., Br. J. Pharmacol. 118, 1996, pp. 205-207; Knoflach et al., J. Neuroscience 16, 1996, pp. 6657-6664).

After intercerebroventricular application, the nociceptin peptide exhibits pronociceptive and hyperalgesic activity in various animal models (Reinscheid et al., Science 270, 1995, pp. 792-794; Hara et al., Br. J. Pharmacol. 121, 1997, pp. 401-408). These findings may be explained as inhibition of stress-induced analgesia (Mogil et al., Neurosci. Letters 214, 1996, pp. 131-134; and also Neuroscience 75, 1996, pp. 333-337). In this connection, anxiolytic activity of the nociceptin could

also be demonstrated (Jenck et al., Proc. Natl. Acad. Sci. USA 94, 1997, 14854-14858).

On the other hand, an antinociceptive effect of nociceptin could be demonstrated in various animal models, in particular after intrathecal administration. Nociceptin inhibits the activity of kainate- or glutamate-stimulated dorsal root ganglion neurones (Shu et al., Neuropeptides, 32, 1998, 567-571) or glutamate-stimulated spinal cord neurones (Faber et al., Br. J. Pharmacol., 119, 1996, pp. 189-190); it has an antinociceptive effect in the tail flick test in mice (King et al., Neurosci. Lett., 223, 1997, 113-116), in the flexor-reflex model in rats (Xu et al., NeuroReport, 7, 1996, 2092-2094) and in the formalin test on rats (Yamamoto et al., Neuroscience, 81, 1997, pp. 249-254). In models of neuropathic pain, an antinociceptive effect of nociceptin, which is of interest in so far as the effectiveness of nociceptin increases after axotomy of spinal nerves, could be demonstrated (Yamamoto and Nozaki-Taguchi, Anesthesiology, 87, 1997). This is in contrast to conventional opioids, of which the effectiveness decreases under these conditions (Abdulla and Smith, J. Neurosci., 18, 1998, pp. 9685-9694).

The ORL1 receptor also participates in the regulation of further physiological and pathophysiological processes. These include learning and memory formation (Sandin et al., Eur. J. Neurosci., 9, 1997, pp. 194-197; Manabe et al., Nature, 394, 1997, pp. 577-581), hearing ability (Nishi et al., EMBO J., 16, 1997, pp. 1858-1864), assimilation of food (Pomonis et al., NeuroReport, 8, 1996, pp. 369-371), regulation of blood pressure (Gumusel et al., Life Sci., 60, 1997, pp. 141-145; Campion and Kadowitz, Biochem. Biophys. Rep. Comm., 234, 1997, pp. 309-312), epilepsy (Gutierrez et al. Abstract 536.18, Society for Neuroscience, Vol 24, 28th Ann. Meeting, Los Angeles, 7-12 November 1998) and diuresis (Kapisa et al., Life Sciences, 60, 1997, PL 15-21). In an article by Calo et al. (Br. J. Pharmacol., 129, 2000, 1261-1283) an overview is given of the indications or biological processes in which the ORL1 receptor plays a part or could very probably play a part. These include: analgesia, stimulation and regulation of food assimilation, influence on μ agonist such as morphine, treatment of withdrawal symptoms, reduction of addiction


potential of morphines, anxiolysis, modulation of movement activity, memory defects, epilepsy; modulation of neurotransmitter discharge, in particular of glutamate, serotonin and dopamine, and therefore neurodegenerative diseases; influencing of the cardiovascular system, triggering of an erection, diuresis, antinatriuresis, electrolyte management, arterial blood pressure, water retention diseases, intestinal motility (diarrhoea), relaxing effects on the respiratory tracts, micturation reflex (urinary incontinence). The use of agonist and antagonist as anoretics, analgesics (also in co-administration with opioids) or nootropics, but also as antitussives is also discussed.

10

The possible applications of compounds which bind to the ORL1 receptor and activate or inhibit it are correspondingly varied.

It was an object of the present invention to provide active ingredients which act on the nonciceptin/ORL1 receptor system and are therefore suitable for pharmaceutical compositions, in particular for treating the various diseases associated with this system according to the prior art or for use in the indications mentioned therein.

20 The invention accordingly relates to substituted 4-aminocyclohexanols described hereinafter as substance group A according to general formula I,



wherein

25 R^1 and R^2 independently of one another are selected from H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or

unsubstituted C₁₋₈-alkyl or C₃₋₈-cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C₁₋₃-alkylene, C₃₋₈-cycloalkyl or heteroaryl; wherein R¹ and R² may not both be H,

5

or the radicals R¹ and R² together form a ring and represent CH₂CH₂OCH₂CH₂, CH₂CH₂NR⁵CH₂CH₂ or (CH₂)₃₋₆,

where R⁵ is selected from H; respectively saturated or unsaturated, branched or
10 unbranched, singly or multiply substituted or unsubstituted C₁₋₈-alkyl or C₃₋₈-cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C₁₋₃-alkylene, C₃₋₈-cycloalkyl or heteroaryl;

15 R³ is selected from respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R⁴ is selected from respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl; -CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷, -
20 CHR⁶-CH₂-CH₂-CH₂R⁷, -C(Y)R⁷, -C(Y)-CH₂R⁷, -C(Y)-CH₂-CH₂R⁷ or -C(Y)-CH₂-CH₂-CH₂R⁷; or -R⁸-L-R⁹

where Y = O, S or H₂,

25 where R⁶ is selected from

H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₇-alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C(O)O-C₁₋₆-alkyl;

30

where R⁷ is selected from

H; respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl
or
heteroaryl,

5

where R⁸ is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

10 where L is selected from

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

where R⁹ is selected from

15

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

provided that,

20 - (disclaimer group 1) if R³ = substituted or unsubstituted phenyl, and R⁴ =
substituted or unsubstituted phenyl or -CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷,
-CHR⁶-CH₂-CH₂-CH₂R⁷, -C(Y)R⁷,
-C(Y)-CH₂R⁷, -C(Y)-CH₂-CH₂R⁷ or -C(Y)-CH₂-CH₂-CH₂R⁷

where Y = H₂

25 R⁶ = H, saturated or unsaturated, branched or unbranched, singly or multiply
substituted or unsubstituted C₁₋₅-alkyl,

and/or

R⁷ = H, respectively substituted or unsubstituted C₃₋₈-cycloalkyl or phenyl,

30 R¹ and R² independently of one another are not both C₁₋₅-alkyl,

24272-152


6

- (disclaimer group 2) if R^3 = substituted or unsubstituted thiophenyl,
and R^4 = $-\text{CH}_2\text{-CH}_2\text{-phenyl}$

the radicals R^1 and R^2 do not together form a ring and represent
 $(\text{CH}_2)_5$,

- 5 optionally in the form of their racemates, their pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular the enantiomers or diastereomers, in any mixing ratio; in the prepared form or in the form of their acids or bases or in the form of their salts, in particular the physiologically acceptable salts or in the form of their
10 solvates, in particular the hydrates.

According to one aspect of the present invention, there is provided a substituted 4-aminocyclohexanol of general formula I,



I

wherein

- 15 R^1 and R^2 independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl; wherein R^1 and R^2 are not
20 both H,

24272-152

6a

or the radicals R^1 and R^2 together form a ring and represent $\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2$, $\text{CH}_2\text{CH}_2\text{NR}^5\text{CH}_2\text{CH}_2$ or $(-\text{CH}_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

$-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$; or $-\text{R}^8-\text{L}-\text{R}^9$

where $\text{Y} = \text{O}$, S or H_2 ,

where R^6 is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $\text{C}(\text{O})\text{O}-\text{C}_{1-6}$ -alkyl;

where R^7 is H; or respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

where R^8 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is $-\text{C}(\text{O})-\text{NH}-$, $-\text{NH}-\text{C}(\text{O})-$, $-\text{C}(\text{O})-\text{O}-$, $-\text{O}-\text{C}(\text{O})-$, $-\text{O}-$, $-\text{S}-$ or $-\text{S}(\text{O})_2-$,

where R^9 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

provided that,

• 29732-87

6b

•
- if R^3 = substituted or unsubstituted phenyl, and R^4 = phenyl or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$

where $\text{Y} = \text{H}_2$

5 R^6 = H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-5} -alkyl,

and

R^7 = H, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or phenyl, then

10 R^1 and R^2 independently of one another are not both C_{1-5} -alkyl; and

- if R^3 = substituted or unsubstituted thiophenyl, and R^4 = $-\text{CH}_2-\text{CH}_2$ -phenyl, then

the radicals R^1 and R^2 do not together form a ring and represent $(\text{CH}_2)_5$,

15 wherein "singly or multiply substituted aryl or heteroaryl" means "aryl or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN , NO_2 , $\text{NR}^{83}\text{R}^{84}$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-8} cycloalkoxy, C_{3-8} cycloalkyl or C_{2-6} alkylene",

wherein

R^{82} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are not themselves substituted with aryl or heteroaryl radicals;

R^{83} and R^{84} are the same or different and represent H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are not themselves substituted with aryl or heteroaryl radicals,

29732-87

6c


or the radicals R^{83} and R^{84} together represent $\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2$, $\text{CH}_2\text{CH}_2\text{NR}^{85}\text{CH}_2\text{CH}_2$ or $(\text{CH}_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are not themselves substituted with aryl or heteroaryl radicals;

“singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

and

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof.

According to another aspect of the present invention, there is provided use of a substituted 4-aminocyclohexanol of general formula I,



I

wherein

R^1 and R^2 independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

wherein R^1 and R^2 are not both H,

24272-152

6d

or the radicals R^1 and R^2 together form a ring and represent $\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2$, $\text{CH}_2\text{CH}_2\text{NR}^5\text{CH}_2\text{CH}_2$ or $(\text{CH}_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply

5 substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R^4 is respectively unsubstituted or singly or multiply substituted

10 C_{3-8} -cycloalkyl, aryl or heteroaryl;

$-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$,
 $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or
 $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$; or $-\text{R}^8-\text{L}-\text{R}^9$

where $\text{Y} = \text{O}, \text{S}$ or H_2 ,

15 where R^6 is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $\text{C}(\text{O})\text{O}-\text{C}_{1-6}$ -alkyl;

where R^7 is H; or respectively unsubstituted or singly or multiply

20 substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

where R^8 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is $-\text{C}(\text{O})-\text{NH}-$, $-\text{NH}-\text{C}(\text{O})-$, $-\text{C}(\text{O})-\text{O}-$, $-\text{O}-\text{C}(\text{O})-$, $-\text{O}-$,
 $-\text{S}-$ or $-\text{S}(\text{O})_2-$

25 where R^9 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

29732-87

6e

wherein “singly or multiply substituted aryl or heteroaryl” means “aryl or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN, NO_2 , $NR^{83}R^{84}$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-8} cycloalkoxy, C_{3-8} cycloalkyl or C_{2-6} alkylene”,

wherein

5 R^{82} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

10 R^{83} and R^{84} are the same or different and represent H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

15 or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

“singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

20 and

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,


25 for treatment of a phobia, stress, a syndrome associated with stress, depression, epilepsy, Alzheimer’s disease, senile dementia, general cognitive dysfunction, a learning difficulty, memory loss, symptoms of withdrawal, alcohol

24272-152

6f

abuse, alcohol dependency, drug abuse, drug dependency, medicine abuse, medicine dependency, sexual dysfunction, cardiovascular disease, hypotension, hypertension, tinnitus, pruritus, migraine, defective hearing, defective bowel motility, impaired assimilation of food, anorexia, obesity, a locomotive disorder, diarrhoea, cachexia or urinary incontinence.

According to yet another aspect of the present invention, there is provided use of a substituted 4-aminocyclohexanol of general formula I,



I

wherein

R^1 and R^2 independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

wherein R^1 and R^2 are not both H,

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

29732-87

6g

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

- CHR^6R^7 , - $CHR^6-CH_2R^7$, - $CHR^6-CH_2-CH_2R^7$,
 - $CHR^6-CH_2-CH_2-CH_2R^7$, - $C(Y)R^7$, - $C(Y)-CH_2R^7$, - $C(Y)-CH_2-CH_2R^7$ or
 5 - $C(Y)-CH_2-CH_2-CH_2R^7$; or - R^8-L-R^9

where $Y = O, S$ or H_2 ,

where R^6 is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or
 10 unsubstituted $C(O)O-C_{1-6}$ -alkyl;

where R^7 is H; or respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

where R^8 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

15 where L is - $C(O)-NH-$, - $NH-C(O)-$, - $C(O)-O-$, - $O-C(O)-$, - $O-$, - $S-$ or - $S(O)_2-$

where R^9 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl
 20 or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN , NO_2 , $NR^{83}R^{84}$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-8} cycloalkoxy, C_{3-8} cycloalkyl or C_{2-6} alkylene",

wherein

R^{82} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein
 25 these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

29732-87

6h

R^{83} and R^{84} are the same or different and represent H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

5 or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;


10 “singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

and

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture
15 of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

as a muscle relaxant, anticonvulsant, antitussive or anaesthetic.

According to still another aspect of the present invention, there is provided use of a substituted 4-aminocyclohexanol of general formula I,



I

24272-152

6i

wherein

R^1 and R^2 independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

wherein R^1 and R^2 are not both H,

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

$-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$,
 $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or
 $-C(Y)-CH_2-CH_2-CH_2R^7$; or $-R^8-L-R^9$

where $Y = O, S$ or H_2 ,

where R^6 is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $C(O)O-C_{1-6}$ -alkyl;

where R^7 is H; or respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

29732-87

6j

where R^8 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is -C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

5 where R^9 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN, NO_2 , $NR^{83}R^{84}$, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₈ cycloalkoxy, C₃₋₈ cycloalkyl or C₂₋₆ alkylene",

10 wherein

R^{82} represents H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

15 R^{83} and R^{84} are the same or different and represent H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$,
 20 $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

"singly or multiply substituted cycloalkyl" means "cycloalkyl singly or
 25 multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC₁₋₃ alkyl or C₁₋₃ alkyl",

and

29732-87


6k

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH₂, SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,


5 for diuresis, antinatriuresis or anxiolysis.

According to a further aspect of the present invention, there is provided a method of producing a substituted 4-aminocyclohexanol as described herein comprising the following steps:

- a. a cyclohexane-1,4-dione protected by the groups S¹ and S²
 10 according to formula II is reacted in the presence of a compound of formula HNR⁰¹R⁰² with a cyanide to form a protected N-substituted 1-amino-4-oxo-cyclohexanecarbonitrile derivative according to formula III;




- b. the aminonitrile according to formula III is reacted with an organometallic reagent having the formula metal-R³ to form a compound
 15 according to formula IVa;




29732-87

6l

c. the protective groups S^1 and S^2 are cleaved off from the compound according to formula IVa to form a 4-substituted 4-aminocyclohexanone derivative according to formula IV;



5 d. the 4-substituted 4-aminocyclohexanone derivative according to formula IV is reacted with an organometallic reagent having the formula metal- R^{04} to form a compound according to formula V;



wherein R^3 has the meaning as described herein

10 and

R^{01} and R^{02} independently of one another are H; a protective group; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl; wherein R^{01} and R^{02} are not both H,

15

29732-87

6m

or the radicals R^{01} and R^{02} together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{05}CH_2CH_2$ or $(CH_2)_{3-6}$, where R^{05} is H; a protective group; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively
 5 singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^{04} is H, a protective group; respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl; $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$; or $-R^8-L-R^9$
 10

where $Y = O, S$ or H_2 ,

where R^6 is H, or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl;

and where R^7 is H; or respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,
 15

where R^8 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is $-C(O)-NH-$, $-NH-C(O)-$, $-C(O)-O-$, $-O-C(O)-$, $-O-$,
 20 $-S-$ or $-S(O)_2-$

where R^9 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl, and S^1 and S^2 independently of one another are protective groups or together represent a protective group and where one or more of R^{01} , R^{02} , R^{04} and R^{05} is the protective group, the protective group is removed.

According to yet a further aspect of the present invention, there is provided a method as described herein, wherein the protective group of R^{01} , R^{02} , R^{04} or R^{05} is alkyl, benzyl or a carbamate.
 25

· 29732-87

· 6n

According to still a further aspect of the present invention, there is provided a method as described herein, wherein the protective groups are Fmoc, Z or Boc.

According to another aspect of the present invention, there is
5 provided a method as described herein, wherein the cyanide of step a is potassium cyanide.

According to yet another aspect of the present invention, there is provided a method as described herein, wherein the organometallic reagent of step b is a Grignard or an organolithium reagent.

10 According to still another aspect of the present invention, there is provided a method as described herein, wherein the organometallic reagent of step d is a Grignard or an organolithium reagent.

According to yet another aspect of the present invention, there is provided a method as described herein, wherein S¹ and S² are independently
15 monoacetal.

All these compounds or groups of compounds according to the invention display excellent binding to the ORL1 receptor.

Compounds which display a certain remote structural relationship with the compounds proposed here are known from the following documents:

20 - DE-OS-28 39 891 or the parallel US Patent US 4,366,172 (Lednicer et al.). The aforementioned compounds are described therein as analgesically active, with reference to the ORL1 receptor.

- the parallel articles:

D. Lednicer and P.F. of Voightlunder, J. Med. Chem. 1979, 22, 1157,

25 D. Lednicer, P.F. of Voightlunder and D.E. Emmert, J. Med. Chem. 1980, 23, 424, and

• 29732-87

• 60

D. Lednicer, P.F. of Voightlunder and D.E. Emmert, J. Med. Chem.
1981, 24, 404,

D. Lednicer, P.F. of Voightlunder and D.E. Emmert, J. Med. Chem.
1981, 24, 340,

5 P.F. Von Voightlunder, D. Lednicer, R.A. Lewis and D.D. Gay,
"Endogenous and Exogenous Opiate Agonist and Antagonist", Proc. Int.

Narc. Rep. Club Conf. (1980), Meeting Date 1979, Way E. Long (Ed),
 Publisher: Pergamon, Elmsford, N. Y. International, Pergamon, 1980,
 17-21,

- Kamenka et al., EurJ. Med.Chem.Chim.Ther.; FR; 19; 3; 1984; 255-260

5 and

- Rao M. N. A. and Rao pp. C. Indian Drugs, 1985, 22 (5), 252-257.

US-Patent US 5,304,479 belonging to Lin et al. is also related to the claimed
 compounds. Compounds (disclaimer group 3) in which R^3 is unsubstituted
 10 phenyl, R^4 is selected from $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$ where $\text{Y} = \text{H}_2$, $\text{R}^6 = \text{H}$, saturated or unsaturated,
 branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -
 alkyl, and $\text{R}^7 = \text{H}$ and the radicals R^1 and R^2 together form a ring and
 15 represent $(\text{OH}_2)_5$ are therefore optionally also excluded from substance
 protection. Under certain circumstances, compounds (disclaimer group 4), in
 which R^3 is unsubstituted phenyl, the radicals R^1 and R^2 together form a ring
 and represent $(\text{CH}_2)_5$ and R^4 is selected from $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$ where $\text{Y} = \text{O}$ or S , $\text{R}^6 = \text{H}$, saturated
 20 or unsaturated, branched or unbranched, singly or multiply substituted or
 unsubstituted C_{1-7} -alkyl, or saturated or unsaturated, branched or unbranched,
 singly or multiply substituted or unsubstituted $\text{C}(\text{O})\text{O}-\text{C}_{1-6}$ -alkyl; and $\text{R}^7 = \text{H}$
 may also be excluded from substance protection.

25

Under certain circumstances it may be preferred if the compounds in disclaimer
 group 1 (see above) excluded from protection are worded more broadly and the
 disclaimer accordingly reads:

30 provided that,

- (disclaimer group 1a) if $\text{R}^3 =$ substituted or unsubstituted aryl, and $\text{R}^4 =$ substituted

or unsubstituted phenyl or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{H}_2\text{R}^7$

where $\text{Y} = \text{H}_2$

- 5 $\text{R}^6 = \text{H}$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-5} -alkyl,

and/or

$\text{R}^7 = \text{H}$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or phenyl,

- 10 R^1 and R^2 independently of one another are not both C_{1-5} -alkyl,

provided that,

- 15 - (disclaimer group 1b) if $\text{R}^3 =$ substituted or unsubstituted phenyl, and $\text{R}^4 =$ respectively substituted or unsubstituted C_{3-8} -cycloalkyl or aryl; or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$

where $\text{Y} = \text{H}_2$

- 20 $\text{R}^6 = \text{H}$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-5} -alkyl,

and/or

$\text{R}^7 = \text{H}$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or phenyl,

- 25 R^1 and R^2 independently of one another are not both C_{1-5} -alkyl,

provided that,

- 30 - (disclaimer group 1c) if $\text{R}^3 =$ substituted or unsubstituted phenyl, and $\text{R}^4 =$ respectively substituted or unsubstituted heteroaryl, C_{3-8} -cycloalkyl or aryl; or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$

where $\text{Y} = \text{H}_2$

$R^6 = H$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-5} -alkyl,

and/or

$R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or phenyl,

5

R^1 and R^2 independently of one another are not both C_{1-5} -alkyl,

provided that,

10 - (disclaimer group 1d) if $R^3 =$ substituted or unsubstituted aryl, and $R^4 =$ substituted or unsubstituted aryl, or $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$ where $Y = H_2$

$R^6 = H$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-5} -alkyl,

15

and/or

$R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or phenyl,

R^1 and R^2 independently of one another are not both C_{1-5} -alkyl,

20

provided that,

- (disclaimer group 1e) if $R^3 =$ substituted or unsubstituted phenyl, and $R^4 =$ substituted or unsubstituted phenyl, or $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$

25

where $Y = H_2$

$R^6 = H$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl,

30

and/or

$R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or aryl,

R^1 and R^2 independently of one another are not both C_{1-8} -alkyl,

provided that,

5

- (disclaimer group 1f) if R^3 = substituted or unsubstituted phenyl, and R^4 = substituted or unsubstituted phenyl, or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{C(Y)R}^7$, $-\text{C(Y)-CH}_2\text{R}^7$, $-\text{C(Y)-CH}_2\text{-CH}_2\text{R}^7$ or $-\text{C(Y)-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$

10

where $Y = \text{H}_2$

$R^6 = \text{H}$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl,

and/or

$R^7 = \text{H}$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl, heteroaryl or aryl,

15

R^1 and R^2 independently of one another are not both C_{1-5} -alkyl,

provided that,

20

- (disclaimer group 1g) if R^3 = substituted or unsubstituted aryl, and R^4 = substituted or unsubstituted aryl, or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{C(Y)R}^7$, $-\text{C(Y)-CH}_2\text{R}^7$, $-\text{C(Y)-CH}_2\text{-CH}_2\text{R}^7$ or $-\text{C(Y)-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$ where $Y = \text{H}_2$

$R^6 = \text{H}$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl,

25

and/or

$R^7 = \text{H}$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or aryl,

R^1 and R^2 independently of one another are not both C_{1-8} -alkyl,

30

provided that,

- (disclaimer group 1h) if R^3 = substituted or unsubstituted aryl, and R^4 = substituted or unsubstituted aryl, or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})\text{-CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{-CH}_2\text{-CH}_2\text{R}^7$ or $-\text{C}(\text{Y})\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$

5 where $\text{Y} = \text{H}_2$

R^6 = H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl,

and/or

R^7 = H, respectively substituted or unsubstituted C_{3-8} -cycloalkyl, heteroaryl or aryl

10

R^1 and R^2 independently of one another are not both C_{1-8} -alkyl,

provided that,

15 - (disclaimer group 1j) if R^3 = substituted or unsubstituted aryl, and R^4 = respectively substituted or unsubstituted aryl or C_{3-8} -cycloalkyl, or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})\text{-CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{-CH}_2\text{-CH}_2\text{R}^7$ or $-\text{C}(\text{Y})\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$

where $\text{Y} = \text{H}_2$

20 R^6 = H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl,

and/or

R^7 = H, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or aryl

25 R^1 and R^2 independently of one another are not both C_{1-8} -alkyl,

provided that,

30 - (disclaimer group 1k) if R^3 = substituted or unsubstituted aryl, and R^4 = respectively substituted or unsubstituted aryl, heteroaryl or C_{3-8} -cycloalkyl, or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})\text{-CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{-CH}_2\text{-CH}_2\text{R}^7$ or $-\text{C}(\text{Y})\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$

where $Y = H_2$

$R^6 = H$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl,

and/or

5 $R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or aryl

R^1 and R^2 independently of one another are not both C_{1-8} -alkyl,

provided that,

10

- (disclaimer group 1l) if $R^3 =$ substituted or unsubstituted aryl, and $R^4 =$ respectively substituted or unsubstituted aryl, heteroaryl or C_{3-8} -cycloalkyl, or - CHR^6R^7 , - $CHR^6-CH_2R^7$, - $CHR^6-CH_2-CH_2R^7$, - $CHR^6-CH_2-CH_2-CH_2R^7$, - $C(Y)R^7$, - $C(Y)-CH_2R^7$, - $C(Y)-CH_2-CH_2R^7$ or - $C(Y)-CH_2-CH_2-CH_2R^7$

15

where $Y = H_2$

$R^6 = H$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl,

and/or

$R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl, heteroaryl or aryl

20

R^1 and R^2 independently of one another are not both C_{1-8} -alkyl,

provided that,

25

- (disclaimer group 1m) if $R^3 =$ substituted or unsubstituted aryl or heteroaryl, and $R^4 =$ respectively substituted or unsubstituted aryl or C_{3-8} -cycloalkyl, or - CHR^6R^7 , - $CHR^6-CH_2R^7$, - $CHR^6-CH_2-CH_2R^7$, - $CHR^6-CH_2-CH_2-CH_2R^7$, - $C(Y)R^7$, - $C(Y)-CH_2R^7$, - $C(Y)-CH_2-CH_2R^7$ or - $C(Y)-CH_2-CH_2-CH_2R^7$

where $Y = H_2$

30

$R^6 = H$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl,

and/or

$R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or aryl

R^1 and R^2 independently of one another are not both C_{1-8} -alkyl,

5

provided that,

- (disclaimer group 1n) if $R^3 =$ substituted or unsubstituted aryl or heteroaryl, and $R^4 =$ substituted or unsubstituted aryl or C_{3-8} -cycloalkyl, or $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$

10

where $Y = H_2$

$R^6 = H$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl,

15

and/or

$R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl, heteroaryl or aryl

R^1 and R^2 independently of one another are not both C_{1-8} -alkyl,

20

provided that

- (disclaimer group 1o) if $R^3 =$ substituted or unsubstituted aryl or heteroaryl, and $R^4 =$ respectively substituted or unsubstituted aryl, heteroaryl or C_{3-8} -cycloalkyl, or $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$

25

where $Y = H_2$

$R^6 = H$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl,

and/or

30

$R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or aryl

R^1 and R^2 independently of one another are not both C_{1-8} -alkyl,

or

provided that,

5

- (disclaimer group 1p) if R^3 = substituted or unsubstituted aryl or heteroaryl, and R^4 = respectively substituted or unsubstituted aryl, heteroaryl or C_{3-8} -cycloalkyl, or - CHR^6R^7 , - $CHR^6-CH_2R^7$, - $CHR^6-CH_2-CH_2R^7$, - $CHR^6-CH_2-CH_2-CH_2R^7$, - $C(Y)R^7$, - $C(Y)-CH_2R^7$, - $C(Y)-CH_2-CH_2R^7$ or - $C(Y)-CH_2-CH_2-CH_2R^7$

10

where $Y = H_2$

$R^6 = H$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl,

and/or

$R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl, heteroaryl or aryl

15

R^1 and R^2 independently of one another are not both C_{1-8} -alkyl.

Under certain circumstances it may be preferred if the compounds excluded from protection in disclaimer group 2 (see above) are worded somewhat more broadly and the disclaimer accordingly reads:

20

provided that

25

- (disclaimer group 2a) if R^3 = substituted or unsubstituted heteroaryl, and $R^4 = -CH_2-CH_2$ -phenyl,

the radicals R^1 and R^2 do not together form a ring and represent $(CH_2)_5$,

provided that

30

- (disclaimer group 2b) if R^3 = substituted or unsubstituted thiophenyl, and $R^4 = -CH_2-CH_2$ -aryl,

the radicals R^1 and R^2 do not together form a ring and represent $(CH_2)_5$,

provided that

5

- (disclaimer group 2c) if R^3 = substituted or unsubstituted thiophenyl, and R^4 = -
 CHR^6R^7 , $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, -
 $C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$

where $Y = H_2$

10

$R^6 = H$ and

R^7 = substituted or unsubstituted phenyl

the radicals R^1 and R^2 do not together form a ring and represent $(CH_2)_5$,

15

provided that

- (disclaimer group 2d) if R^3 = substituted or unsubstituted thiophenyl, and R^4 = -
 CHR^6R^7 , $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, -
 $C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$,

20

where $Y = H_2$

$R^6 = H$ and

R^7 = substituted or unsubstituted phenyl,

the radicals R^1 and R^2 do not together form a ring,

25

provided that

- (disclaimer group 2e) if R^3 = substituted or unsubstituted thiophenyl, and R^4 = -
 CHR^6R^7 , $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, -
30 $C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$,

where $Y = H_2$

$R^6 = H$ and

R^7 = substituted or unsubstituted aryl,

the radicals R^1 and R^2 do not together form a ring,

5 provided that

- (disclaimer group 2f) if R^3 = substituted or unsubstituted thiophenyl, and R^4 = -
 CHR^6R^7 , $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, -
 $C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$

10 where $Y = H_2$

R^6 = H, saturated or unsaturated, branched or unbranched, singly or multiply
substituted or unsubstituted C_{1-7} -alkyl,

and

R^7 = substituted or unsubstituted aryl

15

the radicals R^1 and R^2 do not together form a ring,

provided that

20 - (disclaimer group 2g) if R^3 = substituted or unsubstituted heteroaryl, and R^4 = -
 CHR^6R^7 , $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, -
 $C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$

where $Y = H_2$

R^6 = H or saturated or unsaturated, branched or unbranched, singly or multiply
25 substituted or unsubstituted C_{1-7} -alkyl,

and

R^7 = substituted or unsubstituted phenyl

the radicals R^1 and R^2 do not together form a ring,

30

or

provided that

- (disclaimer group 2h) if R^3 = substituted or unsubstituted heteroaryl, and R^4 = -
 CHR^6R^7 , $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, -
 5 $C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$

where $Y = H_2$

R^6 = H, saturated or unsaturated, branched or unbranched, singly or multiply
 substituted or unsubstituted C_{1-7} -alkyl,

and

10 R^7 = substituted or unsubstituted aryl

the radicals R^1 and R^2 do not together form a ring.

In the context of this invention, alkyl and cycloalkyl radicals are taken to mean
 15 saturated and unsaturated (but not aromatic), branched, unbranched and cyclic
 hydrocarbons which may be unsubstituted or singly or multiply substituted. In this
 case, C_{1-2} -alkyl represents C1- or C2-alkyl, C_{1-3} -alkyl represents C1-, C2- or C3-
 alkyl, C_{1-4} -alkyl represents C1-, C2-, C3- or C4-alkyl, C_{1-5} -alkyl represents C1-, C2-,
 C3-, C4 or C5-alkyl, C_{1-6} -alkyl represents C1-, C2-, C3-, C4-, C5- or C6-alkyl, C_{1-7} -
 20 alkyl represents C1-, C2-, C3-, C4-, C5-, C6- or C7-alkyl, C_{1-8} -alkyl represents
 C1-, C2-, C3-, C4-, C5-, C6-, C7 or C8-alkyl, C_{1-10} -alkyl represents C1-, C2-,
 C3-, C4-, C5-, C6-, C7-, C8-, C9- or C10-alkyl and C_{1-18} -alkyl represents C1-,
 C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, C10-, C11-, C12, C13, C14-, C15-,
 C16-, C17- or C18-alkyl. Furthermore, C_{3-4} -cycloalkyl represents C3- or C4-
 25 cycloalkyl, C_{3-5} -cycloalkyl represents C3-, C4- or C5-cycloalkyl, C_{3-6} -
 cycloalkyl represents C3-, C4-, C5- or C6-cycloalkyl, C_{3-7} -cycloalkyl
 represents C3-, C4-, C5-, C6- or C7-cycloalkyl, C_{3-8} -cycloalkyl represents C3-,
 C4-, C5-, C6-, C7- or C8-cycloalkyl, C_{4-5} -cycloalkyl represents C4- or C5-
 cycloalkyl, C_{4-6} -cycloalkyl represents C4-, C5- or C6-cycloalkyl, C_{4-7} -
 30 cycloalkyl represents C4-, C5-, C6- or C7-cycloalkyl, C_{5-6} -cycloalkyl
 represents C5- or C6-cycloalkyl and C_{5-7} -cycloalkyl represents C5-, C6- or C7-
 cycloalkyl. With respect to cycloalkyl, the term also comprises saturated

cycloalkyls, in which one or two carbon atoms are replaced by a heteroatom, S, N or O. However, the term cycloalkyl also includes, in particular, singly or multiply, preferably singly, unsaturated cycloalkyls without a heteroatom in the ring, if the cycloalkyl is not an aromatic system. The alkyl and cycloalkyl radicals are preferably ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-propenyl, methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, cyclopropyl, 2-methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl, cyclooctyl, but also adamantyl, CHF_2 , CF_3 or CH_2OH and pyrazolinone, oxopyrazolinone, [1,4]dioxan or dioxolan.

In this case, in conjunction with alkyl and cycloalkyl – unless this is not explicitly defined otherwise – the term substituted in the context of this invention is taken to mean the substitution of at least one (optionally also more) hydrogen radical(s) by F, Cl, Br, I, NH_2 , SH or OH, wherein "multiply substituted" or "substituted" with multiple substitution is taken to mean that the substitution is made both on different and on the same atoms multiply with the same or different substituents, for example threefold on the same carbon atom as in the case of CF_3 or at different points as in the case of $-\text{CH}(\text{OH})-\text{CH}=\text{CH}-\text{CHCl}_2$. Particularly preferred substituents in this case are F, Cl and OH. With respect to cycloalkyl, the hydrogen radical can also be replaced by OC_{1-3} alkyl or C_{1-3} alkyl (singly or multiply substituted or unsubstituted respectively), in particular methyl, ethyl, n-propyl, i-propyl, CF_3 , methoxy or ethoxy.

The term $(\text{CH}_2)_{3-6}$ is taken to mean $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ and $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $(\text{CH}_2)_{1-4}$ is taken to mean $-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ and $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $(\text{CH}_2)_{4-5}$ is taken to mean $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ and $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ etc.

An aryl radical is taken to mean ring systems with at least one aromatic ring but without heteroatoms in even only one of the rings. Examples are phenyl,

naphthyl, fluoranthenyl, fluorenyl, tetralinyl or indanyl, in particular 9H fluorenyl or anthracenyl radicals which may be unsubstituted or singly or multiply substituted.

- 5 A heteroaryl radical is taken to mean heterocyclic ring systems with at least one unsaturated ring which contain one or more heteroatoms from the group comprising nitrogen, oxygen and/or sulphur and which can also be singly or multiply substituted. Examples from the group of heteroaryls include furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzo[1,2,5]thiadiazole, 10 benzothiazole, indole, benzotriazole, benzodioxolan, benzodioxan, carbazole, indole and quinazoline.

15 In this case, in conjunction with aryl and heteroaryl, substituted is taken to mean the substitution of the aryl or heteroaryl by R^{82} , OR^{82} a halogen, preferably F and/or Cl, a CF_3 , a CN, a NO_2 , a $NR^{83}R^{84}$, a C_{1-6} -alkyl (saturated), a C_{1-6} -alkoxy, a C_{3-8} -cycloalkoxy, a C_{3-8} -cycloalkyl or a C_{2-6} -alkylene.

20 In this case the radical R^{82} represents H, a C_{1-10} alkyl, preferably a C_{1-6} alkyl, an aryl or heteroaryl radical or an aryl or heteroaryl radical bound by C_{1-3} alkyl, saturated or unsaturated, or a C_{1-3} alkylene-group-bound aryl or heteroaryl radical, wherein these aryl or heteroaryl radicals must not themselves be substituted by aryl or heteroaryl radicals,

25 the radicals R^{83} and R^{84} , which are the same or different, represent H, a C_{1-10} alkyl, preferably a C_{1-6} alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bound by saturated or unsaturated C_{1-3} alkyl or a C_{1-3} alkylene-group-bound aryl or heteroaryl radical, wherein these aryl or heteroaryl radicals must not themselves be substituted by aryl or heteroaryl radicals,

30

or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2HR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and

the radical R⁸⁵ represents H, a C₁₋₁₀ alkyl, preferably a C₁₋₆ alkyl, an aryl radical, a heteroaryl radical or an aryl or heteroaryl radical bound by saturated or unsaturated C₁₋₃ alkyl or a C₁₋₃ alkylene-group-bound aryl or heteroaryl radical, wherein these aryl or heteroaryl radicals must not themselves be substituted by aryl or heteroaryl radicals.

The term salt is taken to mean any form of the active ingredient according to the invention in which it assumes or is charged with an ionic form and is coupled to a counter ion (a cation or anion) or is in solution. This also includes complexes of the active ingredient with other molecules and ions, in particular complexes complexed by ionic interactions. In particular, it includes (and this is also a preferred embodiment of this invention) physiologically acceptable salts, in particular physiologically acceptable salts with cations or bases and physiologically acceptable salts with anions or acids or also a salt formed with a physiologically acceptable acid or a physiologically acceptable cation.

The term physiologically acceptable is taken to mean that the substance, in particular the salt as such, is acceptable when used in humans or mammals, in other word, for example, is not non-physiological (for example toxic).

The term physiologically acceptable salts with anions or acids is taken to mean, in the context of this invention, salts of at least one of the compounds according to the invention – usually protonated, for example on nitrogen – as cation with at least one anion which are physiologically acceptable – in particular when applied to humans and/or mammals. In the context of this invention this is taken to mean, in particular, the salt formed with a physiologically acceptable acid, namely salts of the respective active ingredient with inorganic or organic acids which are physiologically acceptable – in particular when applied to humans and/or mammals. Examples of physiologically acceptable salts of certain acids are salts of: hydrochloric acid, hydrobromic acid, sulphuric acid, methane sulphonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid,

lactic acid, citric acid, glutamic acid, 1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[d]isothiazol-3-one (saccharic acid), monomethyl sebacic acid, 5-oxo-proline, hexane-1-sulphonic acid, nicotinic acid, 2-, 3- or 4-aminobenzoic acid, 2,4,6-trimethyl-benzoic acid, α -lipoic acid, acetyl glycine, acetyl salicylic acid, hippuric acid and/or aspartic acid.


5 The hydrochloride salt is particularly preferred.

The term salt formed with a physiologically acceptable acid in the context of this invention is taken to mean salts of the respective active ingredient with inorganic or organic acids which are physiologically acceptable – in particular when applied to
10 humans and/or mammals. The hydrochloride is particularly preferred. Examples of physiologically acceptable acids include: hydrochloric acid, hydrobromic acid, sulphuric acid, methane sulphonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid, 1,1-dioxo-1,2-dihydro-1 λ ⁶-benzo[d]isothiazol-3-one (saccharic acid),
15 monomethyl sebacic acid, 5-oxo-proline, hexane-1-sulphonic acid, nicotinic acid, 2-, 3- or 4-aminobenzoic acid, 2,4,6-trimethyl-benzoic acid, α -lipoic acid, acetyl glycine, acetyl salicylic acid, hippuric acid and/or aspartic acid.

The term physiologically acceptable salts with cations or bases is taken to mean, in
20 the context of this invention, salts of at least one of the compounds according to the invention – usually a (deprotonated) acid – as anion with at least one, preferably inorganic, cation which are physiologically acceptable, in particular when applied to humans and/or mammals. The salts of the alkali and alkaline earth metals, but also with NH_4^+ are particularly preferred, in particular however (mono) or (di) sodium,
25 (mono) or (di) potassium, magnesium or calcium salts.

The term salt formed with a physiologically acceptable cation in the context of this invention is taken to mean salts of at least one of the respective compounds as anion with at least one inorganic cation which is physiologically acceptable – in particular
30 when applied to humans and/or mammals. The salts of the alkali and alkaline earth metals, but also NH_4^+ are particularly preferred, in particular however (mono) or (di) sodium, (mono) or (di) potassium, magnesium or calcium salts.

The invention accordingly also relates to substituted 4-aminocyclohexanols described hereinafter as substance group A according to general formula I,



5

wherein

the radicals R^1 and R^2 together form a ring and represent $\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2$, $\text{CH}_2\text{CH}_2\text{NR}^5\text{CH}_2\text{CH}_2$ or $(\text{CH}_2)_{3-6}$,

10

where R^5 is selected from H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or heteroaryl;

15

R^3 is selected from respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

20

R^4 is selected from respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl; $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$; or $-\text{R}^8-\text{L}-\text{R}^9$

25

where $\text{Y} = \text{O}, \text{S}$ or H_2 ,

where R^6 is selected from

H, saturated or unsaturated, branched or unbranched, singly or multiply substituted
 5 or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched,
 singly or multiply substituted or unsubstituted $C(O)O-C_{1-6}$ -alkyl;

and where R^7 is selected from

10 H; respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl
 or heteroaryl,

where R^8 is selected from

15 respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is selected from

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-
 20

where R^9 is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

25 provided that,


- (disclaimer group 2) if R^3 = substituted or unsubstituted thiophenyl, and R^4 = -
 CH_2-CH_2 -phenyl

30 the radicals R^1 and R^2 do not together form a ring and represent $(CH_2)_5$,

optionally in the form of their racemates, their pure stereoisomers, in particular

enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular the enantiomers or diastereomers, in any mixing ratio; in the prepared form or in the form of their acids or bases or in the form of their salts, in particular the physiologically acceptable salts or in the form of their solvates, in particular the
 5 hydrates.

The invention accordingly also relates to substituted 4-aminocyclohexanols described hereinafter as substance group C according to general formula I,



10 wherein

R^1 and R^2 independently of one another are selected from H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply
 15 substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or heteroaryl; wherein R^1 and R^2 may not both be H,

R^3 is selected from respectively unsubstituted or singly or multiply substituted aryl
 20 or heteroaryl;

R^4 is selected from respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl; $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-$
 25 $CH_2-CH_2R^7$; or $-R^8-L-R^9$

where Y = O, S or H₂,

where R⁶ is selected from

5

H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₇-alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C(O)O-C₁₋₆-alkyl;

10 and where R⁷ is selected from

H; respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl,

15 where R⁸ is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is selected from

20

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

where R⁹ is selected from

25 respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

provided that,

30 - (disclaimer group 1) if R³ = substituted or unsubstituted phenyl, and R⁴ = phenyl or -CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷, -CHR⁶-CH₂-CH₂-CH₂R⁷, -C(Y)R⁷, -C(Y)-CH₂R⁷, -C(Y)-CH₂-CH₂R⁷ or -C(Y)-CH₂-CH₂-CH₂R⁷

where Y = H₂

$R^6 = H$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-5} -alkyl,

and/or


$R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or phenyl,

5

R^1 and R^2 independently of one another are not both C_{1-5} -alkyl,

optionally in the form of their racemates, their pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular the enantiomers or diastereomers, in any mixing ratio; in the prepared form or in the form of their acids or bases or in the form of their salts, in particular the physiologically acceptable salts or in the form of their solvates, in particular the hydrates.

15 The invention accordingly also relates to substituted 4-aminocyclohexanols described hereinafter as substance group D according to general formula I,



wherein

20

R^1 and R^2 independently of one another are selected from H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or heteroaryl; wherein R^1 and R^2 may not both be H,

25

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$,

- 5 where R^5 is selected from H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or heteroaryl;

10

R^3 is selected from respectively unsubstituted or singly or multiply substituted heteroaryl;

- R^4 is selected from respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl; $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$; or $-R^8-L-R^9$
- 15

where $Y = O, S$ or H_2 ,

20

where R^6 is selected from

- H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $C(O)O-C_{1-6}$ -alkyl;
- 25

where R^7 is selected from

- H; respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,
- 30

where R^8 is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is selected from

5

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

where R⁹ is selected from

10 respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

provided that,

15 - (disclaimer group 2) if R³ = substituted or unsubstituted thiophenyl, and R⁴ = -
CH₂-CH₂-phenyl


the radicals R¹ and R² do not together form a ring and represent (CH₂)₅,

20 optionally in the form of their racemates, their pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular the enantiomers or diastereomers, in any mixing ratio; in the prepared form or in the form of their acids or bases or in the form of their salts, in particular the physiologically acceptable salts or in the form of their solvates, in particular the hydrates.

25

The invention accordingly also relates to substituted 4-aminocyclohexanols described hereinafter as substance group E according to general formula I,

29



wherein

R^1 and R^2 independently of one another are selected from H; respectively saturated
 5 or unsaturated, branched or unbranched, singly or multiply substituted or
 unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply
 substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply
 substituted or unsubstituted aryl bound via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or
 heteroaryl; wherein R^1 and R^2 may not both be H,

10

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$,
 $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$,

where R^5 is selected from H; respectively saturated or unsaturated, branched or
 15 unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -
 cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or
 heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound
 via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or heteroaryl;

20 R^3 is selected from unsubstituted or singly or multiply substituted aryl;

R^4 is selected from respectively unsubstituted or singly or multiply substituted C_{3-8} -
 cycloalkyl, aryl or heteroaryl; $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-$
 $CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-$
 25 $CH_2-CH_2R^7$; or $-R^8-L-R^9$

where Y = O, S or H₂,

where R⁶ is selected from

5

H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₇-alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C(O)O-C₁₋₆-alkyl;

10 where R⁷ is selected from

H; respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl,

15 where R⁸ is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is selected from

20

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

where R⁹ is selected from

25 respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

provided that,

30 - (disclaimer group 1) if R³ = substituted or unsubstituted phenyl, and R⁴ = phenyl or -CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷, -CHR⁶-CH₂-CH₂-CH₂R⁷, -C(Y)R⁷, -C(Y)-CH₂R⁷, -C(Y)-CH₂-CH₂R⁷ or -C(Y)-CH₂-CH₂-CH₂R⁷

where $Y = H_2$

$R^6 = H$, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-5} -alkyl,
and/or


5 $R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or phenyl,

R^1 and R^2 independently of one another are not both C_{1-5} -alkyl,

optionally in the form of their racemates, their pure stereoisomers, in particular
10 enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular the enantiomers or diastereomers, in any mixing ratio; in the prepared form or in the form of their acids or bases or in the form of their salts, in particular the physiologically acceptable salts or in the form of their solvates, in particular the hydrates.

15

The invention accordingly also relates to substituted 4-aminocyclohexanols described hereinafter as substance group F according to general formula I,



20 wherein

the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$,

25 where R^5 is selected from H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -

cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C₁₋₃-alkylene, C₃₋₈-cycloalkyl or heteroaryl;

5 R³ is selected from respectively unsubstituted or singly or multiply substituted aryl;

R⁴ is selected from respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl; -CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷, -CHR⁶-CH₂-CH₂-CH₂R⁷, -C(Y)R⁷, -C(Y)-CH₂R⁷, -C(Y)-CH₂-CH₂R⁷ or -C(Y)-CH₂-CH₂-CH₂R⁷; or -R⁸-L-R⁹

10

where Y = O, S or H₂,

where R⁶ is selected from

15

H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₇-alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C(O)O-C₁₋₆-alkyl;

20 and where R⁷ is selected from

H; respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl,

25 where R⁸ is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is selected from

30

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

where R^9 is selected from


respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

5

optionally in the form of their racemates, their pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular the enantiomers or diastereomers, in any mixing ratio; in the prepared form or in the form of their acids or bases or in the form of their salts, in particular
10 the physiologically acceptable salts or in the form of their solvates, in particular the hydrates.

The invention accordingly also relates to substituted 4-aminocyclohexanols described hereinafter as substance group F according to general formula I,

15



wherein

20 R^1 and R^2 independently of one another are selected from H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or
25 heteroaryl; wherein R^1 and R^2 may not both be H,

R^3 is selected from unsubstituted or singly or multiply substituted heteroaryl;

R^4 is selected from respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl; $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, -
 5 $CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-$
 $CH_2-CH_2R^7$; or $-R^8-L-R^9$

where $Y = O, S$ or H_2 ,

10 where R^6 is selected from

H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $C(O)O-C_{1-6}$ -alkyl;

15

where R^7 is selected from

H; respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

20

where R^8 is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

25 where L is selected from

$-C(O)-NH-$, $-NH-C(O)-$, $-C(O)-O-$, $-O-C(O)-$, $-O-$, $-S-$ or $-S(O)_2-$


where R^9 is selected from

30

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

optionally in the form of their racemates, their pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular the enantiomers or diastereomers, in any mixing ratio; in the prepared
 5 form or in the form of their acids or bases or in the form of their salts, in particular the physiologically acceptable salts or in the form of their solvates, in particular the hydrates.

The invention accordingly also relates to substituted 4-aminocyclohexanols
 10 described hereinafter as substance group H according to general formula I,



wherein

R^1 and R^2 independently of one another are selected from H; respectively saturated
 15 or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or heteroaryl; wherein R^1 and R^2 may not both be H,

20

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$,

where R^5 is selected from H; respectively saturated or unsaturated, branched or
 25 unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or

heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C₁₋₃-alkylene, C₃₋₈-cycloalkyl or heteroaryl;

R³ is selected from respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R⁴ is selected from respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl; -CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷, -CHR⁶-CH₂-CH₂-CH₂R⁷, -C(Y)R⁷, -C(Y)-CH₂R⁷, -C(Y)-CH₂-CH₂R⁷ or -C(Y)-CH₂-CH₂-CH₂R⁷; or -R⁸-L-R⁹

where Y = H₂,

where R⁶ is selected from

H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₇-alkyl

and where R⁷ is selected from

respectively unsubstituted or singly or multiply substituted heteroaryl,

where R⁸ is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is selected from

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-


where R⁹ is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

optionally in the form of their racemates, their pure stereoisomers, in particular
 5 enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular the enantiomers or diastereomers, in any mixing ratio; in the prepared form or in the form of their acids or bases or in the form of their salts, in particular the physiologically acceptable salts or in the form of their solvates, in particular the hydrates.

10

The invention accordingly also relates to substituted 4-aminocyclohexanols described hereinafter as substance group J according to general formula I,



wherein

15

R^1 and R^2 independently of one another are selected from H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply
 20 substituted or unsubstituted aryl bound via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or heteroaryl; wherein R^1 and R^2 may not both be H,

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$,

25

where R^5 is selected from H; respectively saturated or unsaturated, branched or

unbranched, singly or multiply substituted or unsubstituted C₁₋₈-alkyl or C₃₋₈-cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C₁₋₃-alkylene, C₃₋₈-cycloalkyl or heteroaryl;

5

R³ is selected from respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R⁴ is selected from -CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷ or -CHR⁶-CH₂-CH₂-CH₂R⁷,

10

where R⁶ is selected from

or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C(O)O-C₁₋₆-alkyl;

15

and where R⁷ is selected from

H; respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl,

20


optionally in the form of their racemates, their pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular the enantiomers or diastereomers, in any mixing ratio; in the prepared form or in the form of their acids or bases or in the form of their salts, in particular the physiologically acceptable salts or in the form of their solvates, in particular the hydrates.

25

The invention accordingly also relates to substituted 4-aminocyclohexanols described hereinafter as substance group K according to general formula I,

30

39



wherein

R^1 and R^2 independently of one another are selected from H; respectively saturated
 5 or unsaturated, branched or unbranched, singly or multiply substituted or
 unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply
 substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply
 substituted or unsubstituted aryl bound via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or
 heteroaryl; wherein R^1 and R^2 may not both be H,

10

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$,
 $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$,

where R^5 is selected from H; respectively saturated or unsaturated, branched or
 15 unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -
 cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or
 heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound
 via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or heteroaryl;

20 R^3 is selected from respectively unsubstituted or singly or multiply substituted aryl
 or heteroaryl;

R^4 is selected from $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-$
 CH_2R^7 ;

25

where $Y = O$ or S ,

where R^7 is selected from

5 H; respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

optionally in the form of their racemates, their pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular the enantiomers or diastereomers, in any mixing ratio; in the prepared
10 form or in the form of their acids or bases or in the form of their salts, in particular the physiologically acceptable salts or in the form of their solvates, in particular the hydrates.

With respect to substance groups A, D, E, H, J or K, it is preferred if
15

R^1 and R^2 independently of one another are selected from H; saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl; wherein R^1 and R^2 may not both be H,
20 or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$,

where R^5 is selected from H; saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl,
25 preferably

R^1 and R^2 independently of one another are selected from H; saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted
30 C_{1-4} -alkyl; wherein R^1 and R^2 may not both be H,

or the radicals R^1 and R^2 together form a ring and represent $(CH_2)_{4-5}$,

in particular

R^1 and R^2 independently of one another are selected from methyl or ethyl or the
5 radicals R^1 and R^2 together form a ring and represent $(CH_2)_5$.

With respect to substance group C or G, it is preferred if

R^1 and R^2 independently of one another are selected from H; saturated or
10 unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted
 C_{1-8} -alkyl; wherein R^1 and R^2 may not both be H,

preferably

15 R^1 and R^2 independently of one another are selected from H; saturated or
unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted
 C_{1-4} -alkyl; wherein R^1 and R^2 may not both be H,

in particular

20

R^1 and R^2 independently of one another are selected from methyl or ethyl.

With respect to substance group B or F, it is preferred if

25 R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$,
 $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$,

where R^5 is selected from H; saturated or unsaturated, branched or unbranched,
singly or multiply substituted or unsubstituted C_{1-8} -alkyl,

30

preferably

R^1 and R^2 together form a ring and represent $(CH_2)_{4-5}$,

in particular

5

R^1 and R^2 together form a ring and represent $(CH_2)_5$.

With respect to substance groups A, B, C, H, J or K, it is preferred if R^3 is selected from respectively unsubstituted or singly or multiply substituted phenyl, naphthyl, anthracenyl, thiophenyl, benzothiophenyl, pyridyl, furyl, benzofuranyl, benzodioxolanyl, indolyl, indanyl, benzodioxanyl, pyrrolyl, pyrimidyl or pyrazinyl;

preferably

15

R^3 is selected from respectively unsubstituted or singly or multiply substituted phenyl, thiophenyl, pyridyl, furyl, benzofuranyl, benzodioxolanyl, indolyl, indanyl, benzodioxanyl, pyrrolyl, pyrimidyl or pyrazinyl;

20 in particular

R^3 is selected from respectively unsubstituted or singly or multiply substituted phenyl, pyridyl, furyl or thiophenyl.

25 With respect to substance groups D or G, it is preferred if R^3 is selected from respectively unsubstituted or singly or multiply substituted thiophenyl, benzothiophenyl, pyridyl, furyl, benzofuranyl, benzodioxolanyl, indolyl, indanyl, benzodioxanyl, pyrrolyl, pyrimidyl or pyrazinyl;

30 preferably

R^3 is selected from respectively unsubstituted or singly or multiply substituted

thiophenyl, pyridyl, furyl, benzofuranyl, benzodioxolanyl, indolyl, indanyl, benzodioxanyl, pyrrolyl, pyrimidyl or pyrazinyl;

in particular

5

R^3 is selected from respectively unsubstituted or singly or multiply substituted pyridyl, furyl or thiophenyl.

With respect to substance groups E or F, it is preferred if

10

R^3 is selected from phenyl, naphthyl, anthracenyl;

preferably

15 R^3 is selected from respectively unsubstituted or singly or multiply substituted phenyl or naphthyl;

in particular

20 R^3 is selected from unsubstituted or singly or multiply substituted phenyl.

With respect to substance groups A to G, it is preferred if

25 R^4 is selected from respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl; or $-R^8-L-R^9$

preferably

30 R^4 is selected from respectively unsubstituted or singly or multiply substituted cyclobutyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl,

pyridyl, pyrrolyl, pyrazinyl or pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl or benzo[1,2,5]thiazolyl or 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, dioxolanyl, adamantyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl; or $-R^8-L-R^9$

5

in particular

R_4 is selected from respectively unsubstituted or singly or multiply substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiazolyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl; or $-R^8-L-R^9$.

10

With respect to the foregoing embodiment, it is also preferred if

15

R^8 is selected from

respectively unsubstituted or singly or multiply substituted indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl or benzo[1,2,5]thiazolyl or 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl,

20

25

L is selected from

$-C(O)-NH-$, $-NH-C(O)-$, $-C(O)-O-$, $-O-C(O)-$, $-O-$, $-S-$ or $-S(O)_2-$,

30 and/or R^9 is selected from

respectively unsubstituted or singly or multiply substituted indolyl, naphthyl,

benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl or benzo[1,2,5]thiazolyl or 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl,
5 pyrazolinonyl, oxopyrazolinonyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl,

preferably

10 R⁸ is selected from

respectively unsubstituted or singly or multiply substituted indolyl, benzothiophenyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl,

15 L is selected from

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-or -S(O)₂-,

and/or R⁹ is selected from

20

respectively unsubstituted or singly or multiply substituted indolyl, benzothiophenyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl,

in particular

25

R⁸ is selected from

unsubstituted indolyl,

30 L is selected from

-S(O)₂

and R^9 is selected from

unsubstituted phenyl.

5

With respect to substance groups A to G, it is also a preferred embodiment if

R^4 is selected from $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$

10

where $\text{Y} = \text{O}$, S or H_2 ,

preferably

15 R^4 is selected from $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$

where $\text{Y} = \text{O}$ or S ,

20 in particular

R^4 is selected from $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$

where $\text{Y} = \text{O}$.

25

With respect to the foregoing embodiment, it is also preferred if

R^6 is selected from

30 H , saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-4} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $\text{C}(\text{O})\text{O}-\text{C}_{1-4}$ -alkyl;

preferably

5 H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₄-alkyl;

in particular

10 H, CH₃ and C₂H₅.

With respect to the foregoing embodiment, it is also preferred if

15 R⁷ is selected from respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl;

preferably

20 R⁷ is selected from respectively unsubstituted or singly or multiply substituted cyclobutyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl or benzo[1,2,5]thiazolyl or 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, dioxolanyl, adamantyl, 25 pyrimidinyl, quinoliny, isoquinoliny, phthalazinyl or quinazolinyl;

in particular

30 R is selected from respectively unsubstituted or singly or multiply substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl,

acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl.

With respect to substance group H, it is a preferred embodiment if

5

R^4 is selected from respectively unsubstituted or singly or multiply substituted heteroaryl; or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})\text{-CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{-CH}_2\text{-CH}_2\text{R}^7$ or $-\text{C}(\text{Y})\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$; or $\text{R}^8\text{-L-R}^9$

10

where $\text{Y} = \text{H}_2$,

preferably

15 R^4 is selected from respectively unsubstituted or singly or multiply substituted indolyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl or benzo[1,2,5]thiazolyl or 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, 20 oxopyrazolinonyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl;

or $-\text{CHRR}$, $-\text{CHR-CH}_2\text{R}$, $-\text{CHR-CH}_2\text{-CH}_2\text{R}$, $-\text{C}(\text{Y})\text{R}$, $-\text{C}(\text{Y})\text{-CH}_2\text{R}$ or $-\text{C}(\text{Y})\text{-CH}_2\text{-CH}_2\text{R}$

where $\text{Y} = \text{H}_2$,

25

in particular

R^4 is selected from respectively unsubstituted or singly or multiply substituted indolyl, benzofuranyl, benzothiophenyl, benzothiazolyl, indanyl, benzodioxanyl, 30 benzodioxolanyl, acenaphthyl, carbazolyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl; or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$ or $-\text{C}(\text{Y})\text{-CH}_2\text{R}^7$,

where $Y = H_2$.

With respect to the foregoing embodiment, it is also preferred if

5

R^6 is selected from

H, saturated or unsaturated, branched or unbranched, singly or multiply substituted
or unsubstituted C_{1-4} -alkyl;

10

preferably

H, saturated or unsaturated, branched or unbranched, singly or multiply substituted
or unsubstituted C_{1-4} -alkyl;

15

in particular

H, CH_3 and C_2H_5

20 and/or

R^7 is selected from respectively unsubstituted or singly or multiply substituted
indolyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl,
acenaphthyl, carbazolyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl,
25 fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl or benzo[1,2,5]thiazolyl or
1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl,
oxopyrazolinonyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or
quinazolinyl;

30 preferably

R^7 is selected from respectively unsubstituted or singly or multiply substituted

indolyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl;

in particular

5

R^7 is selected from respectively unsubstituted or singly or multiply substituted thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl.

With respect to the foregoing embodiment, it is also preferred if

10

R^8 is selected from

respectively unsubstituted or singly or multiply substituted indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl or benzo[1,2,5]thiazolyl or 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, pyrimidinyl, quinoliny, isoquinoliny, phthalazinyl or quinazolinyl,

20

L is selected from

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-,

25 and/or R^9 is selected from

respectively unsubstituted or singly or multiply substituted indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl or benzo[1,2,5]thiazolyl or 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl,

30

pyrazolinonyl, oxopyrazolinonyl, pyrimidinyl, quinolinyl, isoquinolinyl,
phthalazinyl or quinazolinyl,

preferably

5

R^8 is selected from

respectively unsubstituted or singly or multiply substituted indolyl, benzothiophenyl,
phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl,

10

L is selected from

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)- or -S(O)₂-,

15 and/or R^9 is selected from

respectively unsubstituted or singly or multiply substituted indolyl, benzothiophenyl,
phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl,

20 in particular

R is selected from

unsubstituted indolyl,

25

L is selected from

-S(O)₂-

30 and R is selected from

unsubstituted phenyl.

With respect to substance group J, it is a preferred embodiment if

R^4 is selected from $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$ or $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$

5

preferably

R^4 is selected from $-\text{CHR}^6\text{R}^7$ or $-\text{CHR}^6-\text{CH}_2\text{R}^7$,

10 in particular

R^4 is selected from $-\text{CHR}^6\text{R}^7$.

With respect to the foregoing embodiment, it is also preferred if

15

R^6 is selected from

saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $\text{C}(\text{O})\text{O}-\text{C}_{1-4}\text{-alkyl}$;

20

preferably

saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $\text{C}(\text{O})\text{O}-\text{C}_{1-3}\text{-alkyl}$;

25

in particular

$\text{C}(\text{O})\text{O}-\text{CH}_3$ and $\text{C}(\text{O})\text{O}-\text{C}_2\text{H}_5$

30 and/or

R^7 is selected from respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

5 preferably

R^7 is selected from respectively unsubstituted or singly or multiply substituted cyclobutyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, 10 benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl or benzo[1,2,5]thiazolyl or 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, dioxolanyl, adamantyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl;

15

in particular

R^7 is selected from respectively unsubstituted or singly or multiply substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, 20 benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl,.

With respect to substance group K, it is a preferred embodiment if

25

R^4 is selected from $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$

where $Y = O$

30

preferably

R^4 is selected from $-C(Y)R^7$, $-C(Y)-CH_2R^7$ or $-C(Y)-CH_2-CH_2R^7$,

where $Y = O$

5

in particular

R^4 is selected from $-C(Y)R^7$ or $-C(Y)-CH_2R^7$,

10 where $Y = O$.

With respect to the foregoing embodiment, it is also preferred if

15 R^7 is selected from respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

preferably

20 R^7 is selected from respectively unsubstituted or singly or multiply substituted cyclobutyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl,
25 benzotriazolyl or benzo[1,2,5]thiazolyl or 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, dioxolanyl, adamantyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl;

in particular

30

R^7 is selected from respectively unsubstituted or singly or multiply substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl,

benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl.

- 5 In a preferred embodiment of all the aforementioned substance groups, the substituted 4-aminocyclohexanols according to the invention are selected from the following group:
- 10 • 4-dimethylamino-1-phenethyl-4-phenylcyclohexanol as well as the corresponding hydrochloride,
 - 4-(4-chlorophenyl)-4-dimethylamino-1-phenethylcyclohexanol as well as the corresponding hydrochloride,
 - 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol as well as the corresponding hydrochloride,
 - 15 • 4-dimethylamino-1-(1-methyl-1H-indol-2-yl)-4-phenylcyclohexanol
 - 1-benzo[b]thiophen-2-yl-4-dimethylamino-4-phenylcyclohexanol
 - 1-benzo[b]thiophen-3-yl-4-dimethylamino-4-phenylcyclohexanol
 - 1-(1-benzenesulphonyl-1H-indol-2-yl)-4-dimethylamino-4-phenylcyclohexanol
 - 20 • 1-benzofuran-2-yl-4-dimethylamino-4-phenylcyclohexanol
 - 1-benzothiazol-2-yl-4-dimethylamino-4-phenylcyclohexanol

optionally in the form of their racemates, their pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular the enantiomers or diastereomers, in any mixing ratio; in the prepared form or in the form of their acids or bases or in the form of their salts, in particular the physiologically acceptable salts or in the form of their solvates, in particular the hydrates.

30 The substances according to the invention are toxicologically safe, so they are suitable as a pharmaceutical active ingredient.

The invention therefore also relates to pharmaceutical compositions containing at least one substituted 4-aminocyclohexanol according to the invention, optionally in the form of its racemate, the pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio; in the prepared form or in the form of the acids or bases or in the form of the salts, in particular the physiologically acceptable salts or in the form of their solvates, in particular the hydrates; as well as optionally suitable additives and/or auxiliaries and/or optionally further active ingredients.

10

The pharmaceutical compositions according to the invention contain, in addition to at least one substituted 4-aminocyclohexanol derivative according to the invention, optionally suitable additives and/or auxiliary agents, therefore also excipients, fillers, solvents, diluents, dyes and/or binders and can be administered as liquid pharmaceutical preparations in the form of injection solutions, drops or syrups, as semi-solid pharmaceutical preparations in the form of granules, tablets, pellets, patches, capsules, plasters or aerosols. The choice of auxiliary agents, etc. and the quantities thereof to be used depend on whether the pharmaceutical preparation is to be applied orally, perorally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or topically, for example to the skin, the mucus membranes or the eyes. Preparations in the form of tablets, dragees, capsules, granules, drops and syrups are suitable for oral application, solutions, suspensions, easily reconstitutable dry preparations and sprays are suitable for parenteral, topical and inhalative applications. Substituted 4-aminocyclohexanol derivatives according to the invention in a deposit, in dissolved form or in a plaster, optionally with the addition of agents to promote skin penetration, are suitable percutaneous application preparations. Orally or percutaneously applicable preparation forms can release the substituted 4-aminocyclohexanol derivatives according to the invention after a delay. In principle, other active ingredients known to the person skilled in the art can be added to the pharmaceutical preparations according to the invention.

30

The quantity of active ingredient to be administered to the patient varies as a function of the weight of the patient, the method of application, the indication and the severity of the illness. Conventionally, 0.005 to 1,000 mg/kg, preferably 0.05 to 5 mg/kg of at least one substituted 4-aminocyclohexanol derivative according to the invention are applied.

It is particularly preferred for all the aforementioned forms of the pharmaceutical composition according to the invention if, in addition to at least one substituted 4-aminocyclohexanol, the pharmaceutical composition also contains an opioid, preferably a strong opioid, in particular morphine, or an anaesthetic, preferably hexobarbital or halothane.


In a preferred form of the pharmaceutical composition, a contained substituted 4-aminocyclohexanol according to the invention is present as a pure diastereomer and/or enantiomer, as a racemate or as a non-equimolar or equimolar blend of the diastereomers and/or enantiomers.

As mentioned in the introduction regarding the prior art, the ORL1 receptor has been identified, in particular in the event of pain. Substituted 4-aminocyclohexanol derivatives according to the invention may accordingly be used to produce a pharmaceutical composition for the treatment of pain, in particular acute, visceral, neuropathic or chronic pain.

The invention therefore also relates to the use of a substituted 4-aminocyclohexanol according to general formula I, optionally in the form of its racemate, the pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any mixing ratio; in the prepared form or in the form of the acids or bases or in the form of the salts, in particular the physiologically acceptable salts or in the form of the solvates, in particular the hydrates; for producing a pharmaceutical composition for the treatment of pain, in particular of acute, visceral, neuropathic or chronic pain.

As already mentioned in the introduction, the ORL1 receptor also plays a part in a large number of other physiological processes, in particular those of medical significance, in addition to its role in the event of pain.

- 5 The invention accordingly also relates to the use of a substituted 4-aminocyclohexanol of general formula I,



wherein

10

- R^1 and R^2 independently of one another are selected from H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or heteroaryl; wherein R^1 and R^2 may not both be H,

15

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$,

20

where R^5 is selected from H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted alkylene aryl bound via C_{1-3} , C_{3-8} -cycloalkyl or heteroaryl;

25

R^3 is selected from respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

- 5 R^4 is selected from respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl; $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$; or $-R^8-L-R^9$

- 10 where $Y = O, S$ or H_2 ,

where R^6 is selected from

- 15 H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $C(O)O-C_{1-6}$ -alkyl;

where R^7 is selected from

- 20 H; respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

where R^8 is selected from

- 25 respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is selected from

$-C(O)-NH-$, $-NH-C(O)-$, $-C(O)-O-$, $-O-C(O)-$, $-O-$, $-S-$ or $-S(O)_2-$

30

where R^9 is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

optionally in the form of its racemate, the pure stereoisomers, in particular
5 enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in
particular enantiomers or diastereomers, in any mixing ratio; in the prepared form or
in the form of the acids or bases or in the form of the salts, in particular the
physiologically acceptable salts or in the form of the solvates, in particular the
hydrates; for producing a pharmaceutical composition for the treatment of phobias,
10 stress and syndromes associated with stress, depression, epilepsy, Alzheimer's
disease, senile dementia, general cognitive dysfunction, learning difficulties and
memory loss (as a nootropic), withdrawal symptoms, alcohol and/or drug and/or
medicine abuse and/or dependency, sexual dysfunction, cardiovascular diseases,
hypotension, hypertension, tinnitus, pruritus, migraine, defective hearing, defective
15 bowel motility, impaired assimilation of food, anorexia, obesity, locomotive
disorders, diarrhoea, cachexia, urinary incontinence or as a muscle relaxant,
anticonvulsant, antitussive or anaesthetic or for co-administration during treatment
with an opioid analgaesic or with an anaesthetic, for diuresis or antinatriuresis and/or
anxiolysis.

20

It may be preferred in one of the aforementioned uses if a used substituted 4-
aminocyclohexanol is in the form of a pure diastereomer and/or enantiomer, as a
racemate or as a non-equimolar or equimolar blend of the diastereomers and/or
enantiomers and/or, in addition to the substituted 4-aminocyclohexanol, also
25 contains an opioid, preferably a strong opioid, in particular morphine, or an
anaesthetic, preferably hexobarbital or halothane.

The invention also relates to a method of treating, in particular in one of the
aforementioned indications, a non-human mammal or human which or who requires
30 treatment for pain, in particular chronic pain, by administration of a therapeutically
effective dose of a substituted 4-aminocyclohexanol or of a pharmaceutical
composition according to the invention.


The invention also relates to a method for producing the substituted 4-aminocyclohexanols according to the invention, as stated in the following description and examples.

5

A method comprising the following steps is particularly suitable:

- a. a cyclohexane-1,4-dione protected by the groups S^1 and S^2 according to formula II is reacted in the presence of a compound of formula $HNR^{01}R^{02}$ with a cyanide, preferably potassium cyanide, to form a protected N-substituted 1-amino-4-oxo-cyclohexanecarbonitrile derivative according to formula III;

10




- optionally, the compound is then acylated, alkylated or sulphonated in any sequence and optionally repeatedly and/or, in the case of compounds where R^{01} and/or R^{02} and/or $R^{06} = H$ protected by a protective group, a protective group is cleaved off at least once and optionally acylated, alkylated or sulphonated and/or, in the case of a compound where R^{01} and/or R^{02} and/or $R^{06} = H$, a protective group is introduced at least once and optionally acylated, alkylated or sulphonated,

20

- b. the aminonitrile according to formula III is reacted with organometallic reagents, preferably Grignard or organolithium reagents, having the formula metal- R^3 to form a compound according to formula IVa;


25

62



optionally, the compound is then acylated, alkylated or sulphonated in any sequence and optionally repeatedly and/or, in the case of compounds where R^{01} and/or R^{02} and/or $R^{06} = H$ protected by a protective group, a protective group is cleaved off at least once and optionally acylated, alkylated or sulphonated and/or, in the case of a compound where R^{01} and/or R^{02} and/or $R^{06} = H$, a protective group is introduced at least once and optionally acylated, alkylated or sulphonated,


- c. the protective groups S^1 and S^2 are cleaved off according to formula III on the compound according to formula IVa to form a 4-substituted 4-aminocyclohexanone derivative according to formula IV;



optionally, the compound is then acylated, alkylated or sulphonated in any sequence and optionally repeatedly and/or, in the case of compounds where R^{01} and/or R^{02} and/or $R^{06} = H$ protected by a protective group, a protective group is cleaved off at least once and optionally acylated, alkylated or sulphonated and/or, in the case of a compound where R^{01} and/or R^{02} and/or

$R^{06} = H$, a protective group is introduced at least once and optionally acylated, alkylated or sulphonated,

- d. the 4-substituted 4-aminocyclohexanone derivative according to formula IV is reacted with organometallic reagents, preferably Grignard or organolithium reagents, having the formula metal- R^{04} to form a compound according to formula V;



optionally, the compound is then acylated, alkylated or sulphonated in any sequence and optionally repeatedly and/or, in the case of compounds where R^{01} and/or R^{02} and/or R^{04} and/or R^{05} and/or $R^{06} = H$ protected by a protective group, a protective group is cleaved off at least once and optionally acylated, alkylated or sulphonated and/or, in the case of a compound where R^{01} and/or R^{02} and/or R^{04} and/or R^{05} and/or $R^{06} = H$, a protective group is introduced at least once and optionally acylated, alkylated or sulphonated,

wherein R^1 , R^2 , R^3 and R^4 have the meaning given in claim 1

and

20

R^{01} and R^{02} independently of one another are selected from H; H provided with a protective group; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via C_{1-3} -alkylene, C_{3-8} -cycloalkyl or heteroaryl;

or the radicals R^{01} and R^{02} together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{05}CH_2CH_2$ or $(CH_2)_{3-6}$,

5 where R^{05} is selected from H; H provided with a protective group; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted aryl bound via
10 C_{1-3} -alkylene, C_{3-8} -cycloalkyl or heteroaryl;

R^{04} is selected from H, H provided with a protective group; respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl; $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-$
15 CH_2R^7 , $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-$
 CH_2R^7 ; or $-R^8-L-R^9$

where $Y = O, S$ or H_2 ,

20 where R^6 is selected from

H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl;

25 and where R^7 is selected from

H; respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

30 where R^8 is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is selected from

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

5

where R⁹ is selected from

respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

10

and S¹ and S² independently of one another are selected from protective groups or together represent a protective group, preferably monoacetal.

It is particularly preferred in the aforementioned methods if the protective groups on the H when R⁰¹, R⁰², R⁰⁴ and/or R⁰⁵ are selected from alkyl, benzyl or carbamates, for example FMOC, Z or Boc.

15

Examples

The following examples show compounds according to the invention, their preparation and efficacy tests carried out therewith.

5

In general the following details apply:

The chemicals and solvents used were acquired commercially from conventional suppliers (Acros, Avocado, Aldrich, Fluka, Lancaster, Maybridge, Merck, Sigma, 10 TCI etc.) or synthesised.


Analyses were made by NMR spectroscopy, optionally combined with other methods of analysis such as thin-layer chromatography, mass spectrometry or HPLC.

15

Example 1


General method of producing compounds according to the invention

The compounds are produced, starting from a cyclohexane-1,4-dione II suitably 20 protected as, for example, monoacetal. A protected N-substituted 1-amino-4-oxo-cyclohexane carbonitrile derivative III is obtained by reaction with potassium cyanide in the presence of a secondary amine.




25

The reaction of the aminonitrile III with organometallic reagents, preferably Grignard or organolithium reagents, results in substitution of the nitrile function, so a 4-substituted 4-aminocyclohexanone derivative IV is obtained after subsequently cleaving off the carbonyl protective group.



Type IV intermediates may finally be converted into 4-aminocyclohexanols I according to the invention by addition of organometallic reagents, preferably Grignard organolithium reagents.

10



Example 2

Measurement of the ORL1 bond

15 The 4-aminocyclohexanols of general formula I were investigated in a receptor binding assay with ^3H -nociceptin/Orphanin FQ with membranes of recombinant CHO-ORL1 cells. This test system was carried out by the method presented by

Ardati et al. (Mol. Pharmacol., 51, 1997, pp. 816-824). The concentration of ^3H -nociceptin/Orphanin FQ was 0.5 nM in these tests.

The binding assays were carried out with 20 μg membrane protein per 200 μl mixture in 50 mM Hepes, pH 7.4, 10 mM MgCl_2 and 1 mM EDTA respectively. Binding to the ORL1 receptor was determined using 1 mg WGA-SPA beads (Amersham-Pharmacia, Freiburg), respectively, by incubation of the mixture for one hour at ambient temperature and subsequent measurement in the Trilux scintillation counter (Wallac, Finland). The affinity is indicated as the K_i value.

10

The affinity to the ORL1 receptor was determined according to the specified molecular-pharmacological investigations in each of the following examples 4 to 12. The corresponding K_i values are given in the following table 1.

15 Table 1: ORL1 binding assay data

Example	K_i (nM)
4	4.4
5	10
6	9.0
7	24
8	7.2
9	3.4
10	110
11	66
12	430

Example 3

20 Analgesia test by the tail-flick test on mice

The analgesic effectiveness of the compounds according to the invention was investigated in the focal ray (tail-flick) test on mice by D'Amour and Smith's method (J. Pharm. Exp. Ther. 72, 74 79 (1941)). NMRI mice weighing between 20 and 24 g were used for this purpose. The animals were placed individually in specific test cages and the tail base was exposed to a focused ray of heat from an electric lamp (Tail-flick Typ 55/12/10.fl, Labtec, Dr. Hess). The intensity of the lamp was adjusted such that the time from the switching on of the lamp to the sudden jerking away of the tail (latency of pain) was 3 to 5 seconds in untreated animals. Prior to administration of a compound according to the invention, the animals were pre-tested twice within five minutes and the average value of these measurements was calculated as the pre-test average. The pain was measured 20, 40 and 60 min after intravenous administration. The analgesic effect was determined as an increase in the latency of pain (% MPE) by the following formula:

$$[(T_1 - T_0)/(T_2 - T_0)] \times 100$$

T_0 is the latency time before application of the substance and T_1 the latency time after application, T_2 atng the maximum exposure time (12 sec).

To determine the dose dependency, the respective compound according to the invention was applied in 3 to 5 logarithmically increasing doses, which each concluded the threshold and the maximum active dose, and the ED_{50} values were determined by regression analysis. The ED_{50} was calculated at the peak of action 20 minutes after intravenous administration of the substance.

25

The investigated compounds according to the invention exhibited a pronounced analgesic effect. The results are compiled in the following table.

Example	% MPE	ED_{50}
No.	(intravenous dosage in mg/kg)	intravenous mg/kg
4	100 (0.1)	0.009

5	35 (0.001) 79 (0.01)	0.01 – 0.001
6	43 (0.001) 96 (0.01)	0.001
7	100 (1)	0.19
9	100 (1)	

Example 4**4-dimethylamino-1-phenethyl-4-phenylcyclohexanol**

- 5 Starting with 200 g 1,4-dioxaspiro[4.5]decan-8-one, 168 l aqueous dimethylamine solution (40% by volume), 200 ml methanol, 200 g potassium cyanide and 303 g dimethylamine hydrochloride were added and the reaction mixture was stirred for 65 hours at ambient temperature. The resultant white suspension was extracted four times with 800 ml diethylether in each case, the combined extracts were initially
- 10 concentrated and taken up with 500 ml dichloromethane, the organic phase was separated off, dried over sodium sulphate, filtered, concentrated and substantially freed of solvent residues under vacuum. 265 g 8-dimethylamino-1,4-dioxaspiro[4.5]decane-8-carbonitrile were obtained as a white solid.
- 15 30 g 8-dimethylamino-1,4-dioxaspiro[4.5]decane-8-carbonitrile were dissolved in 300 ml tetrahydrofuran, 143 ml 2.0 molar phenyl magnesium chloride solution in THF were added under a nitrogen atmosphere and stirred overnight at ambient temperature. To work up the mixture, 100 ml ammonium chloride solution (20% by weight) were added with ice cooling, the phases were separated, the aqueous phase
- 20 was extracted twice with 250 ml diethylether in each case, the combined organic phases were dried over sodium sulphate, filtered, concentrated and substantially freed from solvent residues under vacuum. The crude dimethyl-(8-phenyl-1,4-dioxaspiro[4.5]dec-8-yl)amine (34.5 g) obtained was stirred for 48 hours with a mixture of 83 ml concentrated hydrochloric acid (32% by weight) and 48 ml water
- 25 at ambient temperature without further purification. Subsequently the reaction mixture was first washed three times with 50 ml diethylether in each case, then

alkalized by addition of 100 ml sodium hydroxide solution (32% by weight) with ice cooling, extracted three times with 100 ml dichloromethane in each case, the combined dichloromethane extracts were dried over sodium sulphate, filtered, concentrated and substantially freed of solvent residues under vacuum. 18.8 g 4-dimethylamino-4-phenylcyclohexanone were obtained.

3.83 g 4-dimethylamino-4-phenylcyclohexanone dissolved in 10 ml tetrahydrofuran were added dropwise to 21 ml 1.0 molar phenethyl magnesium chloride solution in tetrahydrofuran and the mixture was stirred overnight at ambient temperature. To work up the mixture with ice cooling, 15 ml ammonium chloride solution (20% by weight) were added, the mixture was extracted three times with 15 ml ethylacetate in each case, the extracts were combined, dried over sodium sulphate, filtered, concentrated and substantially freed of solvent residues under vacuum. The crude 4-dimethylamino-1-phenethyl-4-phenylcyclohexanol (5.75 g) obtained was obtained as a brown oil which was chromatographed with diethylether/hexane (V : V = 1 : 1) over silica gel. 1.71 g 4-dimethylamino-1-phenethyl-4-phenylcyclohexanol were obtained in the form of yellow crystals which were dissolved in 6.8 ml 2-butanone and converted by reaction with 26 µl water and 366 µl chlorotrimethylsilane, stirring overnight with subsequent filtration into 838 mg of the corresponding hydrochloride.

Example 5

4-(4-chlorophenyl)-4-dimethylamino-1-phenethylcyclohexanol

Starting with 38 ml 1.0 molar 4-chlorophenyl magnesium chloride solution in diethylether, 4.00 g 8-dimethylamino-1,4-dioxaspiro[4.5]decane-8-carbonitrile, dissolved in 60 ml diethylether, were added dropwise and stirred overnight at ambient temperature. To work up the mixture, 30 ml ammonium chloride solution (20% by weight) were added with ice cooling, the phases were separated, the ethereal phase was washed in succession with 30 ml water and saturated sodium chloride solution, dried over sodium sulphate, filtered, concentrated and substantially freed of solvent residues under vacuum. The crude [8-(4-

chlorophenyl)-1,4-dioxaspiro[4.5]dec-8-yl]dimethylamine (4.18 g) obtained was initially stirred for 24 hours with a mixture of 10 ml concentrated hydrochloric acid (32% by weight) and 6.0 ml water at ambient temperature without further purification and then heated for 3 hours to reflux. Subsequently the reaction mixture
5 was first washed three times with 50 ml diethylether in each case, then made basic by addition of concentrated ammonia solution (25% by weight) with ice cooling, extracted three times with 100 ml diethylether in each case, the combined diethylether extracts were dried over sodium sulphate, filtered, concentrated and substantially freed of solvent residues under vacuum. 3.84 g 4-(4-chlorophenyl)-4-
10 dimethylaminocyclohexanone were obtained as a brown oil.

3.50 g 4-(4-chlorophenyl)-4-dimethylaminocyclohexanone dissolved in 20 ml tetrahydrofuran were added dropwise to 17 ml 1.0 molar phenethyl magnesium chloride solution in tetrahydrofuran and the mixture was stirred overnight at ambient
15 temperature. To work up the mixture, 25 ml ammonium chloride solution (20% by weight) were added with ice cooling, the phases were separated, the mixture was extracted three times with 25 ml diethylether in each case, the combined organic phases were dried over sodium sulphate, filtered, concentrated and substantially freed of solvent residues under vacuum. The crude product obtained (4.54 g) was
20 taken up in 50 ml diethylether, extracted three times with 40 ml hydrochloric acid (5% by weight) in each case and the combined extracts were washed twice with 40 ml dichloromethane in each case. The dichloromethane extracts were dried over sodium sulphate, filtered, concentrated and substantially freed of solvent residues under vacuum. 1.77 g of a yellow resin were obtained and chromatographed with
25 diethylether/hexane (V : V = 2 : 1) over silica gel. The 417 mg 4-(4-chlorophenyl)-4-dimethylamino-1-phenethylcyclohexanol obtained were dissolved in 4.8 ml 2-butanone and converted by reaction with 162 µl chlorotrimethylsilane and 12 µl water, stirring overnight with subsequent filtration, diethylether washing and vacuum drying into 416 mg of the corresponding hydrochloride.

30

Example 64-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol

26.6 g 4-bromoiodbenzene were placed in 150 ml diethylether and 47 ml 2.0 molar isopropyl magnesium chloride solution were added dropwise at ambient temperature. After one further hour, 18 g 8-dimethylamino-1,4-dioxaspiro[4.5]decane-8-carbonitrile, dissolved in 250 ml diethylether, were added dropwise and stirred overnight. To work up the mixture with ice cooling, 20 ml ammonium chloride solution (20% by weight) were added, extracted three times with 100 ml diethylether in each case, the combined organic phases were dried over sodium sulphate, filtered, concentrated and substantially freed of solvent residues under vacuum. The crude product (21.8 g) obtained was chromatographed with diethylether over silica gel. 7.49 g 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol were obtained as a colourless liquid.

7.48 g 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol were dissolved in 30 ml diisopropylether and 10 ml diethylether and were stirred for 4 days with 13 ml 4-molar hydrochloric acid. To work up the reaction mixture, it was alkalized by addition of sodium hydroxide solution (32% by weight), extracted three times with 30 ml dichloromethane in each case, the combined extracts were dried over sodium sulphate, filtered, concentrated and substantially freed of solvent residues under vacuum. The 5.02 g 4-(4-bromophenyl)-4-dimethylaminocyclohexanone obtained, dissolved in 22 ml tetrahydrofuran, were added dropwise to 18 ml 1.0 molar phenethyl magnesium chloride solution in THF in a nitrogen atmosphere at ambient temperature and were stirred overnight. To work up the mixture with ice cooling, 28 ml ammonium chloride solution (20% by weight) were added, the phases were separated, the mixture was extracted three times with 25 ml diethylether in each case, the combined organic phases were dried over sodium sulphate, filtered, concentrated and substantially freed of solvent residues under vacuum. The crude product obtained (5.83 g) was taken up in 50 ml diethylether, extracted three times with 40 ml hydrochloric acid (5% by weight) in each case and the combined extracts were washed twice with 40 ml dichloromethane in each case. The dichloromethane extracts were dried over sodium sulphate, filtered, concentrated and substantially freed of solvent residues under vacuum. 3.66

g of a light brown resin were obtained and were chromatographed with diethylether/hexane (V : V = 2 : 1) over silica gel. The 1.38 g 4-(4-bromophenyl)-4-dimethylaminocyclohexanone obtained were dissolved in 20 ml 2-butanone and converted by reaction with 474 µl chlorotrimethylsilane and 34 µl water, stirring overnight with subsequent filtration, diethylether washing and vacuum drying, into 1.47 mg of the corresponding hydrochloride.

Example 7

4-dimethylamino-1-(1-methyl-1H-indol-2-yl)-4-phenylcyclohexanol

10

A solution of N-methylindol (400 mg, 3.05 mmol) in dry THF (20 ml) was cooled to -5°C under a stream of argon. *Tert*-butyllithium (3.65 mmol, 2.15 ml of a 1.7 molar pentane solution) was added dropwise in such a way that a reaction temperature of 0°C was not exceeded. Once all the substance had been added, the reaction mixture was stirred for 2 hours at 0°C. A solution of 4-dimethylamino-4-phenylcyclohexanone (662 mg, 3.05 mmol) in dry THF (5 ml) was added dropwise at 0°C. The mixture was stirred for 15 minutes at 0°C and then 4 hours at ambient temperature. The reaction mixture was quenched with saturated ammonium chloride solution (20 ml), the organic phase was separated and the aqueous phase extracted four times with dichloromethane (20 ml). The combined organic phases were dried over sodium sulphate, filtered and the solvent removed under vacuum. Purification was carried out by flash chromatography with cyclohexane/ethylacetate (V : V = 7 : 3) over silica gel. 318 mg 4-dimethylamino-1-(1-methyl-1H-indol-2-yl)-4-phenylcyclohexanol with a melting point of 163-165°C were obtained.

25

Example 8

1-benzo[b]thiophen-2-yl-4-dimethylamino-4-phenylcyclohexanol

A solution of benzo[b]thiophene (400 mg, 2.98 mmol) in dry THF (20 ml) was cooled to -5°C under a stream of argon. *Tert*-butyllithium (3.58 mmol, 2.11 ml of a 1.7 molar pentane solution) was carefully added dropwise, to avoid exceeding a reaction temperature of 0°C. Once all the substance had been added, the reaction

30

mixture was stirred for 2 hours at 0°C. A solution of 4-dimethylamino-4-phenylcyclohexanone (648 mg, 2.98 mmol) in dry THF (5 ml) was then added dropwise at 0°C. The mixture was stirred for 15 minutes at 0°C and then 6 hours at ambient temperature. The reaction mixture was quenched with saturated ammonium chloride solution (20 ml), the organic phase was separated and the aqueous phase extracted four times with dichloromethane (20 ml). The combined organic phases were dried over sodium sulphate, filtered and the solvent was removed under vacuum. Purification was carried out by flash chromatography over silica gel with cyclohexane/ethylacetate (V : V = 1 : 1). 345 mg 1-benzo[b]thiophen-2-yl-4-dimethylamino-4-phenylcyclohexanol with a melting point of 183-185°C were obtained.

Example 9

1-benzo[b]thiophen-3-yl-4-dimethylamino-4-phenylcyclohexanol

15

A solution of 3-bromo-1-benzo[b]thiophene (1.00 g, 4.69 mmol) in 30 ml dry tetrahydrofuran was cooled to -78°C under a stream of argon. *n*-butyllithium (5.63 mmol, 3.52 ml of a 15 % by weight hexane solution) were added dropwise in such a way that a reaction temperature of -75°C was not exceeded. Once all the substance had been added, the reaction mixture was stirred for 2 hours at 78°C. A solution of 4-dimethylamino-4-phenylcyclohexanone (1.02 g, 4.69 mmol) in dry THF (15 ml) was added dropwise at 78°C. The reaction mixture was stirred for 2 hours at -78°C and then thawed within about 10 hours at ambient temperature. The reaction mixture was quenched with saturated ammonium chloride solution (30 ml), the organic phase was separated and the aqueous phase extracted four times with dichloromethane (25 ml). The combined organic phases were dried over sodium sulphate, filtered and the solvent removed under vacuum. Purification was carried out by flash chromatography with cyclohexane/ethylacetate (V : V = 7 : 3) over silica gel. 445 mg 1-benzo[b]thiophen-3-yl-4-dimethylamino-4-phenylcyclohexanol with a melting point of 176-178°C were obtained.

30

Example 10

1-(1-benzenesulfonyl-1H-indol-2-yl)-4-dimethylamino-4-phenylcyclohexanol

A solution of 1-benzenesulfonyl-1H-indol (600 mg, 2.33 mmol) in dry THF (30 ml) was cooled to -5°C under a stream of argon. *n*-butyllithium (2.79 mmol, 1.75 ml of a 1.6 molar hexane solution) were added dropwise in such a way that a reaction temperature of 0°C was not exceeded. Once all the substance had been added, the reaction mixture was stirred for 2 hours at 0°C. A solution of 4-dimethylamino-4-phenylcyclohexanone (493 mg, 2.33 mmol) in dry THF (5 ml) was added dropwise at 0°C. The mixture was stirred for 1 hour at 0°C and then 3 days at ambient temperature. The reaction mixture was quenched with saturated ammonium chloride solution (20 ml), the organic phase was separated and the aqueous phase extracted four times with dichloromethane (20 ml). The combined organic phases were dried over sodium sulphate, filtered and the solvent removed under vacuum. Purification was carried out by flash chromatography with cyclohexane/ethylacetate (V : V = 1 : 1) over silica gel. 232 mg 1-(1-benzenesulfonyl-1H-indol-2-yl)-4-dimethylamino-4-phenylcyclohexanol with a melting point of 173-176°C were obtained.

Example 111-benzofuran-2-yl-4-dimethylamino-4-phenylcyclohexanol

A solution of benzo[b]furan (1.50 g, 12.7 mmol) in dry THF (50 ml) was cooled to -8°C under a stream of argon. *Tert*-butyllithium (15.2 mmol, 10.2 ml of a 1.5 molar pentane solution) was added dropwise in such a way that a reaction temperature of -5°C was not exceeded. Once all the substance had been added, the reaction mixture was stirred for 2 ½ hours at -5°C. A solution of 4-dimethylamino-4-phenylcyclohexanone (2.76 g, 12.7 mmol) in dry THF (15 ml) was added dropwise at 0°C. The mixture was stirred for 1 hour at 0°C and then 4 days at ambient temperature. The reaction mixture was quenched with saturated ammonium chloride solution (30 ml), the organic phase was separated and the aqueous phase extracted four times with dichloromethane (30 ml). The combined organic phases were dried over sodium sulphate, filtered and the solvent removed under vacuum. Purification was carried out by flash chromatography with cyclohexane/ethylacetate (V : V = 7 :

3) over silica gel. 1.02 g 1-benzofuran-2-yl-4-dimethylamino-4-phenylcyclohexanol with a melting point of 134-137°C were obtained.

Example 12

5 1-benzothiazol-2-yl-4-dimethylamino-4-phenylcyclohexanol


A solution of benzothiazole (622 mg, 4.60 mmol) in dry THF (30 ml) was cooled to -85°C under a stream of argon. *n*-butyllithium (5.52 mmol, 3.45 ml of a 1.6 molar hexane solution) was added dropwise in such a way that a reaction temperature of
10 -78°C was not exceeded. Once all the substance had been added, the reaction mixture was stirred for 2 hours at -80°C. A solution of 4-dimethylamino-4-phenylcyclohexanone (1.00 g, 4.61 mmol) in dry THF (8 ml) was added dropwise at -80°C. The mixture was stirred for 30 minutes at -80°C and then 3 days at ambient temperature. The reaction mixture was quenched with saturated ammonium chloride
15 solution (30 ml), the organic phase was separated and the aqueous phase extracted four times with dichloromethane (30 ml). The combined organic phases were dried over sodium sulphate, filtered and the solvent removed under vacuum. Purification was carried out by flash chromatography with cyclohexane/ethylacetate (V : V = 7 :
3) over silica gel. 746 mg 1-benzothiazol-2-yl-4-dimethylamino-4-phenylcyclohexanol with a melting point of 155-157°C were obtained.
20

24272-152

78

CLAIMS:

1. A substituted 4-aminocyclohexanol of general formula I,



I

wherein

- 5 R^1 and R^2 independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl; wherein R^1 and R^2 are not
10 both H,

- or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(-CH_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply
15 substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

- R^4 is respectively unsubstituted or singly or multiply substituted
20 C_{3-8} -cycloalkyl, aryl or heteroaryl;

29732-87

79

-CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷,
-CHR⁶-CH₂-CH₂-CH₂R⁷, -C(Y)R⁷, -C(Y)-CH₂R⁷, -C(Y)-CH₂-CH₂R⁷ or
-C(Y)-CH₂-CH₂-CH₂R⁷; or -R⁸-L-R⁹

where Y = O, S or H₂,

5 where R⁶ is H, saturated or unsaturated, branched or unbranched,
singly or multiply substituted or unsubstituted C₁₋₇-alkyl; or saturated or
unsaturated, branched or unbranched, singly or multiply substituted or
unsubstituted C(O)O-C₁₋₆-alkyl;

10 where R⁷ is H; or respectively unsubstituted or singly or multiply
substituted C₃₋₈-cycloalkyl, aryl or heteroaryl,

where R⁸ is respectively unsubstituted or singly or multiply
substituted aryl or heteroaryl,

where L is -C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-,
-S- or -S(O)₂-,

15 where R⁹ is respectively unsubstituted or singly or multiply
substituted aryl or heteroaryl,

provided that,

- if R³ = substituted or unsubstituted phenyl, and R⁴ = phenyl or
-CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷, -CHR⁶-CH₂-CH₂-CH₂R⁷, -C(Y)R⁷,
20 -C(Y)-CH₂R⁷, -C(Y)-CH₂-CH₂R⁷ or -C(Y)-CH₂-CH₂-CH₂R⁷

where Y = H₂

R⁶ = H, saturated or unsaturated, branched or unbranched, singly or
multiply substituted or unsubstituted C₁₋₅-alkyl,

and

29732-87

80

$R^7 = H$, respectively substituted or unsubstituted C_{3-8} -cycloalkyl or phenyl, then

R^1 and R^2 independently of one another are not both C_{1-5} -alkyl; and

- if $R^3 =$ substituted or unsubstituted thiophenyl, and

5 $R^4 = -CH_2-CH_2$ -phenyl, then

the radicals R^1 and R^2 do not together form a ring and represent $(CH_2)_5$,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN , NO_2 ,

10 $NR^{83}R^{84}$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-8} cycloalkoxy, C_{3-8} cycloalkyl or C_{2-6} alkylene",

wherein

R^{82} represents H , C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are not themselves substituted with aryl or

15 heteroaryl radicals;

R^{83} and R^{84} are the same or different and represent H , C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are not themselves substituted with aryl or heteroaryl radicals,

20 or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H , C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are not themselves substituted with aryl or heteroaryl radicals;

25 "singly or multiply substituted cycloalkyl" means "cycloalkyl singly or multiply substituted with F , Cl , Br , I , NH_2 , SH , OH , OC_{1-3} alkyl or C_{1-3} alkyl",

and

29732-87

81

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH₂, SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof.

- 5 2. A substituted 4-aminocyclohexanol according to claim 1, wherein the stereoisomer is an enantiomer.
3. A substituted 4-aminocyclohexanol according to claim 1, wherein the stereoisomer is a diastereomer.
4. A substituted 4-aminocyclohexanol according to claim 1, wherein the
10 mixture of stereoisomers is a mixture of enantiomers.
5. A substituted 4-aminocyclohexanol according to claim 1, wherein the mixture of stereoisomers is a mixture of diastereomers.
6. A substituted 4-aminocyclohexanol according to claim 1, wherein the mixture of stereoisomers is a racemate.
- 15 7. A substituted 4-aminocyclohexanol according to claim 1, wherein the salt is a physiologically acceptable salt.
8. A substituted 4-aminocyclohexanol according to claim 1, wherein the solvate is a hydrate.
9. A substituted 4-aminocyclohexanol according to any one of
20 claims 1 to 8, wherein the radicals R¹ and R² together form the ring and represent CH₂CH₂OCH₂CH₂, CH₂CH₂NR⁵CH₂CH₂ or (CH₂)₃₋₆.
10. A substituted 4-aminocyclohexanol according to any one of
claims 1 to 8, wherein R¹ and R² are independently of one another H; C₁₋₈ alkyl or
C₃₋₈ cycloalkyl, respectively saturated or unsaturated, branched or linear, singly or
25 multiply substituted or unsubstituted; aryl or heteroaryl, respectively singly or
multiply substituted or unsubstituted; or C₁-C₃-alkylene-bound aryl, C₃₋₈ cycloalkyl
or heteroaryl, respectively singly or multiply substituted or unsubstituted; wherein
R¹ and R² are not both H.

29732-87

82

11. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, wherein R^3 is heteroaryl, respectively unsubstituted or singly or multiply substituted.

12. A substituted 4-aminocyclohexanol according to any one of
5 claims 1 to 8, wherein R^3 is selected from aryl, unsubstituted or singly or multiply substituted.

13. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, wherein the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$ and R^3 is aryl, respectively
10 unsubstituted or singly or multiply substituted.

14. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, wherein R^1 and R^2 are independently of one another H; C_{1-8} alkyl or C_{3-8} cycloalkyl, respectively saturated or unsaturated, branched or linear, singly or multiply substituted or unsubstituted; aryl or heteroaryl, respectively singly or
15 multiply substituted or unsubstituted; or C_1 - C_3 -alkylene-bound aryl, C_{3-8} cycloalkyl or heteroaryl, respectively singly or multiply substituted or unsubstituted; wherein R^1 and R^2 may not both be H and R^3 is heteroaryl, respectively unsubstituted or singly or multiply substituted.

15. A substituted 4-aminocyclohexanol according to any one of
20 claims 1 to 8, wherein R^7 is heteroaryl, respectively unsubstituted or singly or multiply substituted.

16. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, wherein R^4 is $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$ or $-CHR^6-CH_2-CH_2-CH_2R^7$, where R^6 is $C(O)O-C_{1-6}$ alkyl, saturated or unsaturated,
25 branched or linear, singly or multiply substituted or unsubstituted.

17. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, wherein R^4 is $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$, where $Y = O$ or S .

29732-87

83

18. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, 11, 12, 15, 16 and 17, wherein R^1 and R^2 independently of one another are H; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl; wherein R^1 and R^2 are not both H,
 5 or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$, where R^5 is H; saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl.
19. A substituted 4-aminocyclohexanol according to claim 18, wherein R^1 and R^2 independently of one another are H; saturated or unsaturated, branched
 10 or unbranched, singly or multiply substituted or unsubstituted C_{1-4} -alkyl; wherein R^1 and R^2 are not both H,
 or the radicals R^1 and R^2 together form a ring and represent $(CH_2)_{4-5}$.
20. A substituted 4-aminocyclohexanol according to claim 18, wherein R^1 and R^2 independently of one another are methyl or ethyl or the radicals
 15 R^1 and R^2 together form a ring and represent $(CH_2)_5$.
21. A substituted 4-aminocyclohexanol according to claim 10 or 14, wherein R^1 and R^2 independently of one another are H; saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl; wherein R^1 and R^2 are not both H.
- 20 22. A substituted 4-aminocyclohexanol according to claim 10 or 14, wherein R^1 and R^2 independently of one another are H; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-4} -alkyl; wherein R^1 and R^2 are not both H.
23. A substituted 4-aminocyclohexanol according to claim 10 or 14,
 25 wherein R^1 and R^2 independently of one another are methyl or ethyl.
24. A substituted 4-aminocyclohexanol according to claim 9 or 13, wherein R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$, where R^5 is H; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl.

29732-87

84

25. A substituted 4-aminocyclohexanol according to claim 9 or 13, wherein R¹ and R² together form a ring and represent (CH₂)₄₋₅.

26. A substituted 4-aminocyclohexanol according to claim 9 or 13, wherein R¹ and R² together form a ring and represent (CH₂)₅.

5 27. A substituted 4-aminocyclohexanol according to any one of claims 1 to 10 and 15 to 17, wherein R³ is respectively unsubstituted or singly or multiply substituted phenyl, naphthyl, anthracenyl, thiophenyl, benzothiophenyl, pyridyl, furyl, benzofuranyl, benzodioxolanyl, indolyl, indanyl, benzodioxanyl, pyrrolyl, pyrimidyl or pyrazinyl.

10 28. A substituted 4-aminocyclohexanol according to any one of claims 1 to 10 and 15 to 17, wherein R³ is respectively unsubstituted or singly or multiply substituted phenyl, thiophenyl, pyridyl, furyl, benzofuranyl, benzodioxolanyl, indolyl, indanyl, benzodioxanyl, pyrrolyl, pyrimidyl or pyrazinyl.

15 29. A substituted 4-aminocyclohexanol according to any one of claims 1 to 10 and 15 to 17, wherein R³ is respectively unsubstituted or singly or multiply substituted phenyl, pyridyl, furyl or thiophenyl.

30. A substituted 4-aminocyclohexanol according to claim 11 or 14, wherein R³ is respectively unsubstituted or singly or multiply substituted thiophenyl, benzothiophenyl, pyridyl, furyl, benzofuranyl, benzodioxolanyl, indolyl, 20 indanyl, benzodioxanyl, pyrrolyl, pyrimidyl or pyrazinyl.

31. A substituted 4-aminocyclohexanol according to claim 11 or 14, wherein R³ is respectively unsubstituted or singly or multiply substituted thiophenyl, pyridyl, furyl, benzofuranyl, benzodioxolanyl, indolyl, indanyl, benzodioxanyl, pyrrolyl, pyrimidyl or pyrazinyl.

25 32. A substituted 4-aminocyclohexanol according to claim 11 or 14, wherein R³ is respectively unsubstituted or singly or multiply substituted pyridyl, furyl or thiophenyl.

29732-87

85

33. A substituted 4-aminocyclohexanol according to claim 12 or 13, wherein R^3 is phenyl, naphthyl or anthracenyl.

34. A substituted 4-aminocyclohexanol according to claim 12 or 13, wherein R^3 is respectively unsubstituted or singly or multiply substituted phenyl or
5 naphthyl.

35. A substituted 4-aminocyclohexanol according to claim 12 or 13, wherein R^3 is unsubstituted or singly or multiply substituted phenyl.

36. A substituted 4-aminocyclohexanol according to any one of claim 1 to 14, wherein R^4 is respectively unsubstituted or singly or multiply
10 substituted C_{3-8} -cycloalkyl, aryl or heteroaryl; or $-R^8-L-R^9$.

37. A substituted 4-aminocyclohexanol according to any one of claims 1 to 14, wherein R^4 is respectively unsubstituted or singly or multiply substituted cyclobutyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl,
15 benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl, benzo[1,2,5]thiazolyl, 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, dioxolanyl, adamantyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl; or $-R^8-L-R^9$.

20 38. A substituted 4-aminocyclohexanol according to any one of claims 1 to 14, wherein R_4 is respectively unsubstituted or singly or multiply substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiazolyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl,
25 pyrrolyl, pyrazinyl or pyrimidyl; or $-R^8-L-R^9$.

39. A substituted 4-aminocyclohexanol according to any one of claims 36 to 38, wherein one or more of:

R^8 is

29732-87

86

respectively unsubstituted or singly or multiply substituted indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl, benzo[1,2,5]thiazolyl, 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl,

L is

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-,10 and R⁹ is

respectively unsubstituted or singly or multiply substituted, indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl, benzo[1,2,5]thiazolyl, 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl.

40. A substituted 4-aminocyclohexanol according to any one of claims 36 to 38, wherein one or more of:

20 R⁸ is

respectively unsubstituted or singly or multiply substituted, indolyl, benzothiophenyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl,

L is

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)- or -S(O)₂-,25 and R⁹ is

respectively unsubstituted or singly or multiply substituted indolyl, benzothiophenyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl.

29732-87

87

41. A substituted 4-aminocyclohexanol according to any one of claims 36 to 38, wherein one or more of:

R^8 is

unsubstituted indolyl,

5 L is

$-S(O)_2$

and R^9 is

unsubstituted phenyl.

42. A substituted 4-aminocyclohexanol according to any one of
10 claims 1 to 14, wherein

R^4 is $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$,
 $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or
 $-C(Y)-CH_2-CH_2-CH_2R^7$

where $Y = O, S$ or H_2 .

15 43. A substituted 4-aminocyclohexanol according to any one of claims 1 to 14, wherein

R^4 is $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-C(Y)R^7$,
 $-C(Y)-CH_2R^7$ or $-C(Y)-CH_2-CH_2R^7$

where $Y = O$ or S .

20 44. A substituted 4-aminocyclohexanol according to any one of claims 1 to 14, wherein

R^4 is $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-C(Y)R^7$ or $-C(Y)-CH_2R^7$

where $Y = O$.

29732-87

88

45. A substituted 4-aminocyclohexanol according to any one of claims 42 to 44, wherein

R^6 is

H; saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-4} -alkyl; or

saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $C(O)O-C_{1-4}$ -alkyl.

46. A substituted 4-aminocyclohexanol according to any one of claims 42 to 44, wherein

R^6 is H or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-4} -alkyl.

47. A substituted 4-aminocyclohexanol according to any one of claims 42 to 44, wherein

R^6 is H, CH_3 or C_2H_5 .

48. A substituted 4-aminocyclohexanol according to any one of claims 42 to 44, wherein

R^7 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl.

49. A substituted 4-aminocyclohexanol according to any one of claims 42 to 44, wherein

R^7 is respectively unsubstituted or singly or multiply substituted cyclobutyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl,

29732-87

89

benzotriazolyl, benzo[1,2,5]thiazolyl, 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, dioxolanyl, adamantyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl.

50. A substituted 4-aminocyclohexanol according to any one of
5 claims 42 to 47, wherein

R^7 is respectively unsubstituted or singly or multiply substituted
cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl,
benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl,
acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or
10 pyrimidyl.

51. A substituted 4-aminocyclohexanol according to claim 15, wherein

R^4 is respectively unsubstituted or singly or multiply substituted
heteroaryl; or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$,
 $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or
15 $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$; or $-\text{R}^8-\text{L}-\text{R}^9$

where $\text{Y} = \text{H}_2$.

52. A substituted 4-aminocyclohexanol according to claim 15, wherein

R^4 is respectively unsubstituted or singly or multiply substituted
indolyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl,
20 acenaphthyl, carbazolyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidyl,
fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl, benzo[1,2,5]thiazolyl,
1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl,
oxopyrazolinonyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl;
or $-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-$
25 $\text{CH}_2-\text{CH}_2\text{R}^7$

where $\text{Y} = \text{H}_2$.

53. A substituted 4-aminocyclohexanol according to claim 15, wherein

29732-87

90

R^4 is respectively unsubstituted or singly or multiply substituted indolyl, benzofuranyl, benzothiophenyl, benzothiazolyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl; or $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-C(Y)R^7$ or $-C(Y)-CH_2R^7$,

5 where $Y = H_2$.

54. A substituted 4-aminocyclohexanol according to any one of claims 51 to 53, wherein one or both of:

R^6 is

10 H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-4} -alkyl;

and

R^7 is respectively unsubstituted or singly or multiply substituted indolyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidyl, 15 fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl, benzo[1,2,5]thiazolyl, 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl.

55. A substituted 4-aminocyclohexanol according to claim 54, wherein

20 R^7 is respectively unsubstituted or singly or multiply substituted indolyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl.

56. A substituted 4-aminocyclohexanol according to claim 54, wherein

R^7 is respectively unsubstituted or singly or multiply substituted thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl.

25 57. A substituted 4-aminocyclohexanol according to any one of claims 54 to 56, wherein R^6 is H, CH_3 or C_2H_5 .

29732-87

91

58. A substituted 4-aminocyclohexanol according to any one of claims 51 to 53, wherein one or more of:

R⁸ is respectively unsubstituted or singly or multiply substituted indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl, benzo[1,2,5]thiazolyl, 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, pyrimidinyl, quinoliny, isoquinoliny, phthalazinyl or quinazolinyl,

10 L is

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-,

and R⁹ is

respectively unsubstituted or singly or multiply substituted indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl, benzo[1,2,5]thiazolyl, 1,2-dihydroacenaphthenyl, pyridinyl, furanyl, benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, pyrimidinyl, quinoliny, isoquinoliny, phthalazinyl or quinazolinyl.

20 59. A substituted 4-aminocyclohexanol according to any one of claims 51 to 53, wherein one or more of:

R⁸ is

respectively unsubstituted or singly or multiply substituted indolyl, benzothiophenyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl;

25 L is

-C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)- or -S(O)₂-,

29732-87

92

and R⁹ is

respectively unsubstituted or singly or multiply substituted indolyl, benzothiophenyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl.

60. A substituted 4-aminocyclohexanol according to any one of
5 claims 51 to 53, wherein:

R⁸ is

unsubstituted indolyl,

L is

-S(O)₂-

- 10 and R⁹ is

unsubstituted phenyl.

61. A substituted 4-aminocyclohexanol according to claim 16, wherein

R⁴ is -CHR⁶R⁷, -CHR⁶-CH₂R⁷ or -CHR⁶-CH₂-CH₂R⁷.

62. A substituted 4-aminocyclohexanol according to claim 16, wherein

- 15 R⁴ is -CHR⁶R⁷ or -CHR⁶-CH₂R⁷.

63. A substituted 4-aminocyclohexanol according to claim 16, wherein

R⁴ is -CHR⁶R⁷.

64. A substituted 4-aminocyclohexanol according to any one of
claims 61 to 63, wherein one or more of

- 20 R⁶ is

saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C(O)O-C₁₋₄-alkyl;

29732-87

93

and

R^7 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl.

65. A substituted 4-aminocyclohexanol according to any one of
5 claims 61 to 63, wherein one or more of

 R^6 is

saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $C(O)O-CH_3$;

and

- 10 R^7 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl.

66. A substituted 4-aminocyclohexanol according to claim 64 or 65, wherein

- R^7 is respectively unsubstituted or singly or multiply substituted
cyclobutyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
15 anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl,
benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl,
pyridyl, pyrrolyl, pyrazinyl, pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl,
benzotriazolyl, benzo[1,2,5]thiazolyl, 1,2-dihydroacenaphthenyl, pyridinyl, furanyl,
benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, dioxolanyl, adamantyl, pyrimidinyl,
20 quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl.

67. A substituted 4-aminocyclohexanol according to claim 64 or 65, wherein

- R^7 is respectively unsubstituted or singly or multiply substituted
cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl,
benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl,
25 acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or
pyrimidyl.

29732-87

94

68. A substituted 4-aminocyclohexanol according to any one of claims 64 to 67, wherein R^6 is $C(O)O-CH_3$ or $C(O)O-C_2H_5$.

69. A substituted 4-aminocyclohexanol according to claim 17, wherein

R^4 is $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)CH_2-CH_2R^7$ or
5 $-C(Y)-CH_2-CH_2-CH_2R^7$

where $Y = O$.

70. A substituted 4-aminocyclohexanol according to claim 17, wherein

R^4 is $-C(Y)R^7$, $-C(Y)-CH_2R^7$ or $-C(Y)-CH_2-CH_2R^7$,

where $Y = O$.

10 71. A substituted 4-aminocyclohexanol according to claim 17, wherein

R^4 is $-C(Y)R^7$ or $-C(Y)-CH_2R^7$,

where $Y = O$.

72. A substituted 4-aminocyclohexanol according to any one of claims 69 to 71, wherein

15 R^7 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl.

73. A substituted 4-aminocyclohexanol according to any one of claims 69 to 71, wherein

R^7 is respectively unsubstituted or singly or multiply substituted
20 cyclobutyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidyl, fluorenyl, fluoranthenyl, benzothiazolyl, benzotriazolyl, benzo[1,2,5]thiazolyl, 1,2-dihydroacenaphthenyl, pyridinyl, furanyl,
25 benzofuranyl, pyrazolinonyl, oxopyrazolinonyl, dioxolanyl, adamantyl, pyrimidinyl, quinolinyl, isoquinolinyl, phthalazinyl or quinazolinyl.

29732-87

95

74. A substituted 4-aminocyclohexanol according to any one of claims 69 to 71, wherein

R^7 is respectively unsubstituted or singly or multiply substituted cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, anthracenyl, indolyl, naphthyl, benzofuranyl, benzothiophenyl, indanyl, benzodioxanyl, benzodioxolanyl, acenaphthyl, carbazolyl, phenyl, thiophenyl, furyl, pyridyl, pyrrolyl, pyrazinyl or pyrimidyl.

75. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, wherein the 4-aminocyclohexanol is 4-dimethylamino-1-(1-methyl-1H-indol-2-yl)-4-phenylcyclohexanol.

76. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, wherein the 4-aminocyclohexanol is 1-benzo[b]thiophen-2-yl-4-dimethylamino-4-phenylcyclohexanol.

77. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, wherein the 4-aminocyclohexanol is 1-benzo[b]thiophen-3-yl-4-dimethylamino-4-phenylcyclohexanol.

78. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, wherein the 4-aminocyclohexanol is 1-(1-benzenesulphonyl-1H-indol-2-yl)-4-dimethylamino-4-phenylcyclohexanol.

79. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, wherein the 4-aminocyclohexanol is 1-benzofuran-2-yl-4-dimethylamino-4-phenylcyclohexanol.

80. A substituted 4-aminocyclohexanol according to any one of claims 1 to 8, wherein the 4-aminocyclohexanol is 1-benzothiazol-2-yl-4-dimethylamino-4-phenylcyclohexanol.

81. A pharmaceutical composition comprising a 4-aminocyclohexanol as defined in any one of claims 1 to 80 and a pharmaceutically acceptable carrier or diluent.

29732-87

96

82. A pharmaceutical composition according to claim 81, further comprising an opioid or an anaesthetic.

83. A pharmaceutical composition according to claim 82, wherein the opioid is morphine.

5 84. A pharmaceutical composition according to claim 82, wherein the anaesthetic is hexobarbital or halothane.

85. A pharmaceutical composition according to any one of claims 81 to 84 for treatment of pain.

10 86. A pharmaceutical composition according to claim 85, wherein the pain is acute, visceral, neuropathic or chronic pain.

87. A pharmaceutical composition according to any one of claims 81 to 84 for treatment of a migraine.

88. A pharmaceutical composition according to any one of claims 81 to 84 for treatment of a locomotive disorder.

15 89. A pharmaceutical composition according to any one of claims 81 to 84 that is an anticonvulsant.

90. A pharmaceutical composition according to any one of claims 81 to 84 that is a muscle relaxant.

20 91. A use of a substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 in preparation of a pharmaceutical composition for treatment of pain.

92. A use according to claim 91, wherein the pain is acute, visceral, neuropathic or chronic pain.

25 93. A use of a substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 in preparation of a pharmaceutical composition for treatment of a migraine.

29732-87

97

94. A use of a substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 in preparation of a pharmaceutical composition for treatment of a locomotive disorder.

95. A use of a substituted 4-aminocyclohexanol as defined in any one of
5 claims 1 to 80 in preparation of a pharmaceutical composition that is a muscle relaxant.

96. A use of a substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 in preparation of a pharmaceutical composition that is an anticonvulsant.

10 97. A use of a substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 for treatment of pain.

98. A use according to claim 97, wherein the pain is acute, visceral, neuropathic or chronic pain.

99. A use of a substituted 4-aminocyclohexanol as defined in any one of
15 claims 1 to 80 for treatment of a migraine.

100. A use of a substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 for treatment of a locomotive disorder.

101. A use of a substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 that is a muscle relaxant.

20 102. A use of a substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 that is an anticonvulsant.

103. A substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 for treatment of pain.

104. A substituted 4-aminocyclohexanol according to claim 103, wherein
25 the pain is acute visceral, neuropathic or chronic pain.

105. A substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 for treatment of a migraine.

29732-87


98

106. A substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 for treatment of a locomotive disorder.

107. A substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 that is a muscle relaxant.

5 108. A substituted 4-aminocyclohexanol as defined in any one of claims 1 to 80 that is an anticonvulsant.

109. Use of a substituted 4-aminocyclohexanol of general formula I,



I

wherein

10 R^1 and R^2 independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

15 wherein R^1 and R^2 are not both H,

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

20

29732-87

99

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

5 $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$,
 $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or
 $-C(Y)-CH_2-CH_2-CH_2R^7$; or $-R^8-L-R^9$

where $Y = O, S$ or H_2 ,

10 where R^6 is H, saturated or unsaturated, branched or unbranched,
singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or
unsaturated, branched or unbranched, singly or multiply substituted or
unsubstituted $C(O)O-C_{1-6}$ -alkyl;

where R^7 is H; or respectively unsubstituted or singly or multiply
substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

15 where R^8 is respectively unsubstituted or singly or multiply
substituted aryl or heteroaryl,

where L is $-C(O)-NH-$, $-NH-C(O)-$, $-C(O)-O-$, $-O-C(O)-$, $-O-$,
 $-S-$ or $-S(O)_2-$

20 where R^9 is respectively unsubstituted or singly or multiply
substituted aryl or heteroaryl,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl
or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN , NO_2 ,
 $NR^{83}R^{84}$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-8} cycloalkoxy, C_{3-8} cycloalkyl or C_{2-6} alkylene",

wherein

25 R^{82} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl
radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein

29732-87

100

these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

R^{83} and R^{84} are the same or different and represent H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or
 5 unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or
 10 unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

“singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

and


15 “singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

in preparation of a pharmaceutical composition for treatment of a
 20 phobia, stress, a syndrome associated with stress, depression, epilepsy, Alzheimer’s disease, senile dementia, general cognitive dysfunction, a learning difficulty, memory loss, symptoms of withdrawal, alcohol abuse, alcohol dependency, drug abuse, drug dependency, medicine abuse, medicine dependency, sexual dysfunction, cardiovascular disease, hypotension,
 25 hypertension, tinnitus, pruritus, migraine, defective hearing, defective bowel motility, impaired assimilation of food, anorexia, obesity, a locomotive disorder, diarrhoea, cachexia or urinary incontinence.

29732-87

101

110. Use of a substituted 4-aminocyclohexanol of general formula I,



I

wherein

R^1 and R^2 independently of one another are H; respectively

5 saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

wherein R^1 and R^2 are not both H,

10 or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

20 $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$; or $-R^8-L-R^9$

29732-87

102

where Y = O, S or H₂,

where R⁶ is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₇-alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C(O)O-C₁₋₆-alkyl;

where R⁷ is H; or respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl,

where R⁸ is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is -C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

where R⁹ is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl or heteroaryl singly or multiply substituted with R⁸², OR⁸², halogen, CF₃, CN, NO₂, NR⁸³R⁸⁴, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₈ cycloalkoxy, C₃₋₈ cycloalkyl or C₂₋₆ alkylene",

wherein

R⁸² represents H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

R⁸³ and R⁸⁴ are the same or different and represent H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

29732-87

103

or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;


“singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

and

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

in preparation of a pharmaceutical composition which acts as a muscle relaxant, anticonvulsant, antitussive or anaesthetic.

111. Use of a substituted 4-aminocyclohexanol of general formula I,



I

wherein

R^1 and R^2 independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

29732-87

104

wherein R^1 and R^2 are not both H,

or the radicals R^1 and R^2 together form a ring and represent $\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2$, $\text{CH}_2\text{CH}_2\text{NR}^5\text{CH}_2\text{CH}_2$ or $(\text{CH}_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

$-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{CHR}^6-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2\text{R}^7$, $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2\text{R}^7$ or $-\text{C}(\text{Y})-\text{CH}_2-\text{CH}_2-\text{CH}_2\text{R}^7$; or $-\text{R}^8-\text{L}-\text{R}^9$

where $\text{Y} = \text{O}$, S or H_2 ,

where R^6 is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $\text{C}(\text{O})\text{O}-\text{C}_{1-6}$ -alkyl;

where R^7 is H; or respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

where R^8 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is $-\text{C}(\text{O})-\text{NH}-$, $-\text{NH}-\text{C}(\text{O})-$, $-\text{C}(\text{O})-\text{O}-$, $-\text{O}-\text{C}(\text{O})-$, $-\text{O}-$, $-\text{S}-$ or $-\text{S}(\text{O})_2-$

where R^9 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

29732-87

105

wherein “singly or multiply substituted aryl or heteroaryl” means “aryl or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN, NO_2 , $NR^{83}R^{84}$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-8} cycloalkoxy, C_{3-8} cycloalkyl or C_{2-6} alkylene”,

wherein

5 R^{82} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

10 R^{83} and R^{84} are the same or different and represent H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, 15 heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

“singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

20 and


“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

25 in preparation of a pharmaceutical composition for diuresis, antinatriuresis or anxiolysis.

29732-87

106

112. Use of a substituted 4-aminocyclohexanol of general formula I,



I

wherein

R^1 and R^2 independently of one another are H; respectively

5 saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

wherein R^1 and R^2 are not both H,

10 or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

20 $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$; or $-R^8-L-R^9$

29732-87

107

where Y = O, S or H₂,

where R⁶ is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₇-alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or
 5 unsubstituted C(O)O-C₁₋₆-alkyl;

where R⁷ is H; or respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl,

where R⁸ is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

10 where L is -C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

where R⁹ is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl
 15 or heteroaryl singly or multiply substituted with R⁸², OR⁸², halogen, CF₃, CN, NO₂, NR⁸³R⁸⁴, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₈ cycloalkoxy, C₃₋₈ cycloalkyl or C₂₋₆ alkylene",

wherein

R⁸² represents H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein
 20 these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

R⁸³ and R⁸⁴ are the same or different and represent H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are
 25 themselves substituted with aryl or heteroaryl radicals,

29732-87

108

or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;


“singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

and

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

for treatment of a phobia, stress, a syndrome associated with stress, depression, epilepsy, Alzheimer’s disease, senile dementia, general cognitive dysfunction, a learning difficulty, memory loss, symptoms of withdrawal, alcohol abuse, alcohol dependency, drug abuse, drug dependency, medicine abuse, medicine dependency, sexual dysfunction, cardiovascular disease, hypotension, hypertension, tinnitus, pruritus, migraine, defective hearing, defective bowel motility, impaired assimilation of food, anorexia, obesity, a locomotive disorder, diarrhoea, cachexia or urinary incontinence.

113. Use of a substituted 4-aminocyclohexanol of general formula I,



I

29732-87

109

wherein

R^1 and R^2 independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

wherein R^1 and R^2 are not both H,

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

$-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$,
 $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or
 $-C(Y)-CH_2-CH_2-CH_2R^7$; or $-R^8-L-R^9$

where $Y = O, S$ or H_2 ,

where R^6 is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $C(O)O-C_{1-6}$ -alkyl;

where R^7 is H; or respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

29732-87

110

where R^8 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is -C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

5 where R^9 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN, NO_2 , $NR^{83}R^{84}$, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₈ cycloalkoxy, C₃₋₈ cycloalkyl or C₂₋₆ alkylene",

10 wherein

R^{82} represents H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

15 R^{83} and R^{84} are the same or different and represent H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

20 or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

25 "singly or multiply substituted cycloalkyl" means "cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC₁₋₃ alkyl or C₁₋₃ alkyl",

and


29732-87

111

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH₂, SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

5 as a muscle relaxant, anticonvulsant, antitussive or anaesthetic.

114. Use of a substituted 4-aminocyclohexanol of general formula I,



I

wherein

R^1 and R^2 independently of one another are H; respectively
 10 saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₈-alkyl or C₃₋₈-cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C₁₋₃-alkylene-bound aryl, C₃₋₈-cycloalkyl or heteroaryl;

wherein R^1 and R^2 are not both H,

15 or the radicals R^1 and R^2 together form a ring and represent CH₂CH₂OCH₂CH₂, CH₂CH₂NR⁵CH₂CH₂ or (CH₂)₃₋₆, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₈-alkyl or C₃₋₈-cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply
 20 substituted or unsubstituted C₁₋₃-alkylene-bound aryl, C₃₋₈-cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

29732-87

112

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

- CHR^6R^7 , - $CHR^6-CH_2R^7$, - $CHR^6-CH_2-CH_2R^7$,
 - $CHR^6-CH_2-CH_2-CH_2R^7$, - $C(Y)R^7$, - $C(Y)-CH_2R^7$, - $C(Y)-CH_2-CH_2R^7$ or
 5 - $C(Y)-CH_2-CH_2-CH_2R^7$; or - R^8-L-R^9

where $Y = O, S$ or H_2 ,

where R^6 is H , saturated or unsaturated, branched or unbranched,
 singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or
 unsaturated, branched or unbranched, singly or multiply substituted or
 10 unsubstituted $C(O)O-C_{1-6}$ -alkyl;

where R^7 is H ; or respectively unsubstituted or singly or multiply
 substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

where R^8 is respectively unsubstituted or singly or multiply
 substituted aryl or heteroaryl,

15 where L is - $C(O)-NH-$, - $NH-C(O)-$, - $C(O)-O-$, - $O-C(O)-$, - $O-$,
 - $S-$ or - $S(O)_2-$

where R^9 is respectively unsubstituted or singly or multiply
 substituted aryl or heteroaryl,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl
 20 or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN , NO_2 ,
 $NR^{83}R^{84}$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-8} cycloalkoxy, C_{3-8} cycloalkyl or C_{2-6} alkylene",

wherein

R^{82} represents H , C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl
 radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein
 25 these aryl and heteroaryl radicals are themselves substituted with aryl or
 heteroaryl radicals;

29732-87

113

R^{83} and R^{84} are the same or different and represent H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

5 or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;


10 “singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

and

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture
15 of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

for diuresis, antinatriuresis or anxiolysis.

115. A substituted 4-aminocyclohexanol of general formula I,



I

29732-87

114

wherein

R^1 and R^2 independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

wherein R^1 and R^2 are not both H,

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

$-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$,
 $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or
 $-C(Y)-CH_2-CH_2-CH_2R^7$; or $-R^8-L-R^9$

where $Y = O, S$ or H_2 ,

where R^6 is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $C(O)O-C_{1-6}$ -alkyl;

where R^7 is H; or respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

29732-87

115

where R^8 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is -C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

5 where R^9 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN, NO_2 , $NR^{83}R^{84}$, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₈ cycloalkoxy, C₃₋₈ cycloalkyl or C₂₋₆ alkylene",

10 wherein

R^{82} represents H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

15 R^{83} and R^{84} are the same or different and represent H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$,
 20 $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

"singly or multiply substituted cycloalkyl" means "cycloalkyl singly or
 25 multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC₁₋₃ alkyl or C₁₋₃ alkyl",

and


29732-87

116

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH₂, SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

- 5 for treatment of a phobia, stress, a syndrome associated with stress, depression, epilepsy, Alzheimer's disease, senile dementia, general cognitive dysfunction, a learning difficulty, memory loss, symptoms of withdrawal, alcohol abuse, alcohol dependency, drug abuse, drug dependency, medicine abuse, medicine dependency, sexual dysfunction, cardiovascular disease, hypotension,
 10 hypertension, tinnitus, pruritus, migraine, defective hearing, defective bowel motility, impaired assimilation of food, anorexia, obesity, a locomotive disorder, diarrhoea, cachexia or urinary incontinence.

116. A substituted 4-aminocyclohexanol of general formula I,



I

15 wherein

R¹ and R² independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₈-alkyl or C₃₋₈-cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply
 20 substituted or unsubstituted C₁₋₃-alkylene-bound aryl, C₃₋₈-cycloalkyl or heteroaryl;

wherein R¹ and R² are not both H,

29732-87

117

or the radicals R^1 and R^2 together form a ring and represent $\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2$, $\text{CH}_2\text{CH}_2\text{NR}^5\text{CH}_2\text{CH}_2$ or $(\text{CH}_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

$-\text{CHR}^6\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{CHR}^6\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{R}^7$, $-\text{C}(\text{Y})\text{-CH}_2\text{R}^7$, $-\text{C}(\text{Y})\text{-CH}_2\text{-CH}_2\text{R}^7$ or $-\text{C}(\text{Y})\text{-CH}_2\text{-CH}_2\text{-CH}_2\text{R}^7$; or $-\text{R}^8\text{-L-R}^9$

where $\text{Y} = \text{O}, \text{S}$ or H_2 ,

where R^6 is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted $\text{C}(\text{O})\text{O-C}_{1-6}$ -alkyl;

where R^7 is H; or respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

where R^8 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is $-\text{C}(\text{O})\text{-NH-}$, $-\text{NH-C}(\text{O})\text{-}$, $-\text{C}(\text{O})\text{-O-}$, $-\text{O-C}(\text{O})\text{-}$, $-\text{O-}$, $-\text{S-}$ or $-\text{S}(\text{O})_2\text{-}$

where R^9 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

29732-87

118

wherein “singly or multiply substituted aryl or heteroaryl” means “aryl or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN, NO_2 , $NR^{83}R^{84}$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-8} cycloalkoxy, C_{3-8} cycloalkyl or C_{2-6} alkylene”,

wherein

5 R^{82} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

10 R^{83} and R^{84} are the same or different and represent H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, 15 heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

“singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

20 and


“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

25 as a muscle relaxant, anticonvulsant, antitussive or anaesthetic.

29732-87

119

117. A substituted 4-aminocyclohexanol of general formula I,



I

wherein

R^1 and R^2 independently of one another are H; respectively

5 saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

wherein R^1 and R^2 are not both H,

10 or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^3 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R^4 is respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl;

20 $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-CH_2R^7$ or $-C(Y)-CH_2-CH_2-CH_2R^7$; or $-R^8-L-R^9$

29732-87

120

where Y = O, S or H₂,

where R⁶ is H, saturated or unsaturated, branched or unbranched,
 singly or multiply substituted or unsubstituted C₁₋₇-alkyl; or saturated or
 unsaturated, branched or unbranched, singly or multiply substituted or
 5 unsubstituted C(O)O-C₁₋₆-alkyl;

where R⁷ is H; or respectively unsubstituted or singly or multiply
 substituted C₃₋₈-cycloalkyl, aryl or heteroaryl,

where R⁸ is respectively unsubstituted or singly or multiply
 substituted aryl or heteroaryl,

10 where L is -C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-,
 -S- or -S(O)₂-

where R⁹ is respectively unsubstituted or singly or multiply
 substituted aryl or heteroaryl,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl
 15 or heteroaryl singly or multiply substituted with R⁸², OR⁸², halogen, CF₃, CN, NO₂,
 NR⁸³R⁸⁴, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₈ cycloalkoxy, C₃₋₈ cycloalkyl or C₂₋₆ alkylene",

wherein

R⁸² represents H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl
 radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein
 20 these aryl and heteroaryl radicals are themselves substituted with aryl or
 heteroaryl radicals;

R⁸³ and R⁸⁴ are the same or different and represent H, C₁₋₁₀ alkyl,
 aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or
 unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are
 25 themselves substituted with aryl or heteroaryl radicals,

29732-87

121

or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;


“singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

and

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

for diuresis, antinatriuresis or anxiolysis.

118. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a substituted 4-aminocyclohexanol of general formula I,



I

wherein

R^1 and R^2 independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply

29732-87

122

substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C₁₋₃-alkylene-bound aryl, C₃₋₈-cycloalkyl or heteroaryl;

wherein R¹ and R² are not both H,

or the radicals R¹ and R² together form a ring and represent

5 CH₂CH₂OCH₂CH₂, CH₂CH₂NR⁵CH₂CH₂ or (CH₂)₃₋₆, where R⁵ is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₈-alkyl or C₃₋₈-cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C₁₋₃-alkylene-bound aryl, C₃₋₈-cycloalkyl or heteroaryl;

10 R³ is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R⁴ is respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl;

15 -CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷,
-CHR⁶-CH₂-CH₂-CH₂R⁷, -C(Y)R⁷, -C(Y)-CH₂R⁷, -C(Y)-CH₂-CH₂R⁷ or
-C(Y)-CH₂-CH₂-CH₂R⁷; or -R⁸-L-R⁹

where Y = O, S or H₂,

20 where R⁶ is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₇-alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C(O)O-C₁₋₆-alkyl;

where R⁷ is H; or respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl,

25 where R⁸ is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is -C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-,
-S- or -S(O)₂-

29732-87

123

where R^9 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

wherein “singly or multiply substituted aryl or heteroaryl” means “aryl or heteroaryl singly or multiply substituted with R^{82} , OR^{82} , halogen, CF_3 , CN, NO_2 , $NR^{83}R^{84}$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-8} cycloalkoxy, C_{3-8} cycloalkyl or C_{2-6} alkylene”,

wherein

R^{82} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

R^{83} and R^{84} are the same or different and represent H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

“singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

and


“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

29732-87

124

for treatment of a phobia, stress, a syndrome associated with stress, depression, epilepsy, Alzheimer's disease, senile dementia, general cognitive dysfunction, a learning difficulty, memory loss, symptoms of withdrawal, alcohol abuse, alcohol dependency, drug abuse, drug dependency, medicine abuse, medicine dependency, sexual dysfunction, cardiovascular disease, hypotension, hypertension, tinnitus, pruritus, migraine, defective hearing, defective bowel motility, impaired assimilation of food, anorexia, obesity, a locomotive disorder, diarrhoea, cachexia or urinary incontinence.

119. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a substituted 4-aminocyclohexanol of general formula I,



I

wherein

R^1 and R^2 independently of one another are H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

wherein R^1 and R^2 are not both H,

or the radicals R^1 and R^2 together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^5CH_2CH_2$ or $(CH_2)_{3-6}$, where R^5 is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted

29732-87

125

or unsubstituted C₁₋₈-alkyl or C₃₋₈-cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C₁₋₃-alkylene-bound aryl, C₃₋₈-cycloalkyl or heteroaryl;

R³ is respectively unsubstituted or singly or multiply substituted aryl
5 or heteroaryl;

R⁴ is respectively unsubstituted or singly or multiply substituted
C₃₋₈-cycloalkyl, aryl or heteroaryl;

-CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷,
-CHR⁶-CH₂-CH₂-CH₂R⁷, -C(Y)R⁷, -C(Y)-CH₂R⁷, -C(Y)-CH₂-CH₂R⁷ or
10 -C(Y)-CH₂-CH₂-CH₂R⁷; or -R⁸-L-R⁹

where Y = O, S or H₂,

where R⁶ is H, saturated or unsaturated, branched or unbranched,
singly or multiply substituted or unsubstituted C₁₋₇-alkyl; or saturated or
unsaturated, branched or unbranched, singly or multiply substituted or
15 unsubstituted C(O)O-C₁₋₆-alkyl;

where R⁷ is H; or respectively unsubstituted or singly or multiply
substituted C₃₋₈-cycloalkyl, aryl or heteroaryl,

where R⁸ is respectively unsubstituted or singly or multiply
substituted aryl or heteroaryl,

20 where L is -C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-,
-S- or -S(O)₂-

where R⁹ is respectively unsubstituted or singly or multiply
substituted aryl or heteroaryl,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl
25 or heteroaryl singly or multiply substituted with R⁸², OR⁸², halogen, CF₃, CN, NO₂,
NR⁸³R⁸⁴, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₈ cycloalkoxy, C₃₋₈ cycloalkyl or C₂₋₆ alkylene",

29732-87

126

wherein

R^{82} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or

5 heteroaryl radicals;

R^{83} and R^{84} are the same or different and represent H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals,

10 or the radicals R^{83} and R^{84} together represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{85}CH_2CH_2$ or $(CH_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

15 “singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,

and


“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture
20 of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

which acts as a muscle relaxant, anticonvulsant, antitussive or anaesthetic.

120. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a substituted 4-aminocyclohexanol of general
25 formula I,

29732-87

127



I

wherein

R¹ and R² independently of one another are H; respectively

- 5 saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₈-alkyl or C₃₋₈-cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C₁₋₃-alkylene-bound aryl, C₃₋₈-cycloalkyl or heteroaryl;

wherein R¹ and R² are not both H,

- 10 or the radicals R¹ and R² together form a ring and represent CH₂CH₂OCH₂CH₂, CH₂CH₂NR⁵CH₂CH₂ or (CH₂)₃₋₆, where R⁵ is H; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₈-alkyl or C₃₋₈-cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C₁₋₃-alkylene-bound aryl, C₃₋₈-cycloalkyl or heteroaryl;
- 15

R³ is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl;

R⁴ is respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl;

- 20 -CHR⁶R⁷, -CHR⁶-CH₂R⁷, -CHR⁶-CH₂-CH₂R⁷,
-CHR⁶-CH₂-CH₂-CH₂R⁷, -C(Y)R⁷, -C(Y)-CH₂R⁷, -C(Y)-CH₂-CH₂R⁷ or
-C(Y)-CH₂-CH₂-CH₂R⁷; or -R⁸-L-R⁹

29732-87

128

where Y = O, S or H₂,

where R⁶ is H, saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C₁₋₇-alkyl; or saturated or unsaturated, branched or unbranched, singly or multiply substituted or
 5 unsubstituted C(O)O-C₁₋₆-alkyl;

where R⁷ is H; or respectively unsubstituted or singly or multiply substituted C₃₋₈-cycloalkyl, aryl or heteroaryl,

where R⁸ is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

10 where L is -C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-, -S- or -S(O)₂-

where R⁹ is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

wherein "singly or multiply substituted aryl or heteroaryl" means "aryl
 15 or heteroaryl singly or multiply substituted with R⁸², OR⁸², halogen, CF₃, CN, NO₂, NR⁸³R⁸⁴, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₈ cycloalkoxy, C₃₋₈ cycloalkyl or C₂₋₆ alkylene",

wherein

R⁸² represents H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein
 20 these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

R⁸³ and R⁸⁴ are the same or different and represent H, C₁₋₁₀ alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C₁₋₃ alkylene group, wherein these aryl and heteroaryl radicals are
 25 themselves substituted with aryl or heteroaryl radicals,

29732-87

129

or the radicals R^{83} and R^{84} together represent $\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2$, $\text{CH}_2\text{CH}_2\text{NR}^{85}\text{CH}_2\text{CH}_2$ or $(\text{CH}_2)_{3-6}$, and the radical R^{85} represents H, C_{1-10} alkyl, aryl, heteroaryl or an aryl or heteroaryl radical which is bound via a saturated or unsaturated C_{1-3} alkylene group, wherein these aryl and heteroaryl radicals are themselves substituted with aryl or heteroaryl radicals;

“singly or multiply substituted cycloalkyl” means “cycloalkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH, OH, OC_{1-3} alkyl or C_{1-3} alkyl”,


and

“singly or multiply substituted alkyl” means “alkyl singly or multiply substituted with F, Cl, Br, I, NH_2 , SH or OH”, or a stereoisomer thereof, a mixture of stereoisomers thereof, an acid thereof, a base thereof, a salt thereof or a solvate thereof,

for diuresis, antinatriuresis or anxiolysis.

121. A method of producing a substituted 4-aminocyclohexanol as defined in claim 1 comprising the following steps:


a. a cyclohexane-1,4-dione protected by the groups S^1 and S^2 according to formula II is reacted in the presence of a compound of formula $\text{HNR}^{01}\text{R}^{02}$ with a cyanide to form a protected N-substituted 1-amino-4-oxo-cyclohexanecarbonitrile derivative according to formula III;




29732-87

130

b. the aminonitrile according to formula III is reacted with an organometallic reagent having the formula metal- R^3 to form a compound according to formula IVa;



5 c. the protective groups S^1 and S^2 are cleaved off from the compound according to formula IVa to form a 4-substituted 4-aminocyclohexanone derivative according to formula IV;




d. the 4-substituted 4-aminocyclohexanone derivative according to formula IV is reacted with an organometallic reagent having the formula metal- R^{04} to form a compound according to formula V;

10

29732-87

131



wherein R^3 has the meaning given in claim 1

and

R^{01} and R^{02} independently of one another are H; a protective group;

5 respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl; wherein R^{01} and R^{02} are not both H,

10 or the radicals R^{01} and R^{02} together form a ring and represent $CH_2CH_2OCH_2CH_2$, $CH_2CH_2NR^{05}CH_2CH_2$ or $(CH_2)_{3-6}$, where R^{05} is H; a protective group; respectively saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-8} -alkyl or C_{3-8} -cycloalkyl; respectively singly or multiply substituted or unsubstituted aryl or heteroaryl; or respectively

15 singly or multiply substituted or unsubstituted C_{1-3} -alkylene-bound aryl, C_{3-8} -cycloalkyl or heteroaryl;

R^{04} is H, a protective group; respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl; $-CHR^6R^7$, $-CHR^6-CH_2R^7$, $-CHR^6-CH_2-CH_2R^7$, $-CHR^6-CH_2-CH_2-CH_2R^7$, $-C(Y)R^7$, $-C(Y)-CH_2R^7$, $-C(Y)-CH_2-$

20 CH_2R^7 or $-C(Y)-CH_2-CH_2-CH_2R^7$; or $-R^8-L-R^9$

where $Y = O, S$ or H_2 ,

29732-87

132

where R^6 is H, or saturated or unsaturated, branched or unbranched, singly or multiply substituted or unsubstituted C_{1-7} -alkyl;

and where R^7 is H; or respectively unsubstituted or singly or multiply substituted C_{3-8} -cycloalkyl, aryl or heteroaryl,

5 where R^8 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl,

where L is -C(O)-NH-, -NH-C(O)-, -C(O)-O-, -O-C(O)-, -O-,
-S- or -S(O)₂-

10 where R^9 is respectively unsubstituted or singly or multiply substituted aryl or heteroaryl, and S^1 and S^2 independently of one another are protective groups or together represent a protective group and where one or more of R^{01} , R^{02} , R^{04} and R^{05} is the protective group, the protective group is removed.

122. A method according to claim 121, wherein the protective group on R^{01} , R^{02} , R^{04} or R^{05} is alkyl, benzyl or carbamate.

15 123. A method according to claim 122, wherein the protective group is FMOC, Z or Boc.

124. A method according to any one of claims 121 to 123, wherein the cyanide of step a is potassium cyanide.

20 125. A method according to any one of claims 121 to 124, wherein the organometallic reagent of step b is a Grignard or an organolithium reagent.

126. A method according to any one of claims 121 to 125, wherein the organometallic reagent of step d is a Grignard or an organolithium reagent.

127. A method according to any one of claims 121 to 125, wherein S^1 and S^2 are independently monoacetal.